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Abstract 
 
Parkinson patients have insufficient dopamine in specific regions of the brain, so attempts 
have been made to replenish the deficiency in the dopamine. Dopamine itself doesn't 
cross blood brain barrier, but its precursor, levodopa (LD) is actively transported into the 
CNS and is converted to dopamine in the brain. The bioavailability of LD is less than 
10% with only 1% of administered oral levodopa penetrates the brain. Large doses of 
levodopa are required because much of the drug is decarboxylated to dopamine in the 
periphery, resulting in side effects that include nausea, vomiting, cardiac arrhythmias, 
and hypotension. To minimize the conversion to dopamine (DA) outside the central 
nervous system (CNS), LD is usually co-administered with peripheral inhibitors of amino 
acid decarboxylase (carbidopa or benserazide). In spite of that, other central nervous side 
effects such as dyskinesia, on-off phenomenon and end-of-dose deterioration still remain. 
 
In this project, a number of dopamine prodrugs were designed using DFT molecular 
orbital at B3LYP 6-31G (d, p) levels and molecular mechanics (MM2) calculations 
aiming to provide prodrugs that are expected to give better bioavailability than the 
parental drug owing to improved absorption. Furthermore, the proposed prodrugs are 
believed to be more effective than L-dopa because the latter undergoes decarboxylation 
in the periphery before reaching the blood–brain barrier. 
 
The DFT calculation results revealed that the rate of a proton transfer in processes 
dopamine ProD 1-ProD 5 is largely dependent on the geometric variations of the 
reactant (GM) mainly the distance between the two reactive centers, rGM, and the angle of 
attack α. It was found that systems with low rGM and high α values in their global 
minimum structures, such as ProD 1 and ProD 2, exhibit much higher rates (lower ∆G‡) 
than these with high rGM and low α values, such as ProD 3-ProD 5 and the rate of the 
reaction is linearly correlated with rGM and (1/α). 
 
Moreover, it was found that the intraconversion rate of the designed dopamine prodrugs 
is largely determined on the strain energies of the reaction ̓s tetrahedral intermediates  
iv 
 
(EsINT). Systems having strained tetrahedral intermediates were found to be with low 
rates and vice versa.  
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1. Introduction 
1.1 Prodrug Approach 
1.1.1 Prodrug Concept 
Many therapeutic drugs possess adverse properties that may become pharmacological, 
pharmaceutical or pharmacokinetics barriers in the clinical drug application [1]. There are 
many approaches to eliminate or reduce the undesirable drug properties while retaining 
the desirable therapeutic action, but the prodrug approach offers possibly the highest 
flexibility and has been demonstrated as an important means of improving drug 
efficiency [2]. 
The term prodrug was first introduced in 1958 by Albert [3]. A prodrug is a 
pharmacologically inactive chemical derivative of a drug molecule that converted to its 
active form by enzymatic and/or chemical transformation within the mammalian system 
[4]. Prodrug design may be useful in solving many problems associated with solubility, 
absorption, site specificity, instability, prolonged release, toxicity, poor patient 
acceptability (unpleasant taste or odor, produce gastric irritation or pain, etc) and 
formulation problems [5-8]. 
Prodrugs can be categorized according to two major criteria, chemical classes (carrier-
linked prodrugs, bioprecursors, sit-specific chemical delivery systems, etc.) and 
mechanism of activation (enzymatic versus nonenzymatic, activation by oxidation, 
reduction or hydrolysis, catabolic versus anabolic reaction) [9]. 
 
1.1.2 Prodrug Applications 
1.1.2.1 Improving Solubility of Drugs 
Prodrugs can be used to increase the aqueous solubility of the parent drug molecule by 
attaching ionizable or polar neutral groups, such as phosphates, amino acids, or sugar 
moieties [8, 10-11]. Enzymes such as phosphatases, esterases, glucosidase, amidases or 
peptidases in plasma or other tissues can then breakdown the molecules into its active 
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form. Fosphenytoin is a good example of a prodrug which by the addition of a phosphate 
group has enhanced the aqueous solubility of phenytoin by a factor of 7,000 fold [13]. 
1.1.2.2 Increasing Permeability & Absorption of Drugs 
Prodrug can be utilized to promote membrane permeation and either oral or topical 
absorption by increasing drug lipophilicity via masking polar and ionizable groups within 
a drug molecule [14]. A hydrophilic hydroxyl, thiol, carboxyl, phosphate, or an amine 
group on the parent drug can be transformed to more lipophilic alkyl or aryl esters, and 
these prodrugs are readily converted to the parent drugs via hydrolysis catalyzed by 
esterase enzyme [15-16]. An example of this type of prodrug is oseltamivir which is an 
ethyl ester prodrug and undergoes rapid conversion by carboxylesterase to its 
parent drug. The bioavailability of the more lipophilic oseltamivir is almost 80%, 
whereas the corresponding value for free carboxylate is as low as 5%. [13]. 
Another method to increase the oral absorption is to design prodrugs, which have 
structural features similar to substrates that are absorbed by carrier-mediated transport 
[13]. Enalapril is an example of an ester prodrug which improves the bioavailability from 
3% (active drug) to 40%. The ethyl ester moiety increases lipophilicity and is also a 
substrate of the PEPT1transporter [17]. 
1.1.2.3 Taste Masking 
Bitterness of the drug is the major reason for patient incompliance. In order to eliminate 
the bitter taste of a drug and hence increasing its efficacy, the prodrug approach can be 
used either by decreasing the drug solubility in saliva or by masking the functional group 
that is responsible for the drug’s binding to the taste receptors located on the tongue [18]. 
1.1.2.4 Modifying the Distribution Profile  
The prodrug approach is one of the most promising site-selective drug delivery strategies 
which exploit target cell- or tissue- specific endogenous enzymes and transporters [19]. 
One example is the prodrug capecitabine which is metabolized initially in the liver and 
subsequently in tumor cells to form the anticancer agent 5-fluorouracil [17]. 
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1.1.2.5 Preventing from Rapid Metabolism 
Many oral drugs have low bioavailability due to the first pass metabolism in the 
gastrointestinal tract and liver [20]. The prodrug approach can also protect the rapid 
metabolic breakdown of the drug and thereby increase its oral bioavailability by masking 
the metabolically labile functions [21]. 
1.1.3 Prodrug approaches for the CNS delivery 
 Most therapeutic agents cannot distribute into the brain due to the presence of the blood 
brain barrier (BBB) that is formed by brain capillary endothelial cells. So drugs must 
cross the BBB to enter the brain from the bloodstream [22]. Therapeutic agents to be able 
to cross the BBB should have either physicochemical properties that allow passive 
diffusion through the BBB or have the structural features so that the drug can access one 
of the endogenous BBB transporters and enter the brain [23]. The endogenous BBB 
transport systems are classified as carrier mediated transport, receptor mediated transport 
and active efflux transport [24-27]. Whereas the drug to be able to cross the BBB by 
passive diffusion should be lipid soluble, have a molecular weight < 500 Da, neutral or 
uncharged at physiological pH and be able to form less than eight H-bonds with water 
[28-29]. 
The prodrug strategy is broadly used to optimize physicochemical properties that allow 
for passive diffusion via the transcellular route or to insert structural features necessary to 
serve as a substrate for one of the endogenous influx transport systems [23]. 
 
1.1.3.1 Lipidization Approach  
Prodrug approaches are utilized to increase drug delivery to the brain and used passive 
drug uptake processes by chemically modifying a drug to become more lipophilic, enter 
through BBB more readily, and is then converted back to the parent drug within the 
brain. 
There are two methods to make the drug more lipophilic. First, the polar functional group 
on the drug can be masked by conjugating it with a lipophilic moiety. Second, the drug 
can be conjugated to a lipophilic drug carrier. Both methods of reformulation of the drug 
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lead to the production of a prodrug that is more lipophilic and can cross the BBB, and 
then the drug is metabolized within the brain and release the parent drug. 
Chemical drug delivery system (CDS) is an effective prodrug approach that uses 
improved lipophilicity and requires multiple steps bioactivation for conversion to active 
drugs. It captures the drug inside the brain by converted the prodrug into a more 
hydrophilic derivatives after crossing CNS. Thus decrease the efflux of drug from the 
CNS and provide a sustained release for it [30-31]. 
1.1.3.2 Carrier-Mediated Prodrugs 
There are several endogenous influx transporters at the brain capillary endothelium that 
forms the BBB. These include carrier mediated transport systems from the bloodstream 
to the brain for essential nutrients such as amino acids, glucose and vitamins [32-33]. So 
these membrane transporters can take part in drug transport if the drug molecules have 
similar structural properties to endogenous substrates [33]. 
Carrier-mediated prodrug approach based on linking the parent drug to an endogenous 
transporter substrate so that can be recognized and transported through BBB by 
transporter systems and enters to the CNS [34].  
 
1.1.4 The Problem with Classic Prodrug Approach 
The key problem with the classic prodrug approach is the difficulty in predicting the 
bioconversion rate of the prodrug to the parent drug, and thus its pharmacological or 
toxicological effects. Moreover, it is difficult to predict always the rate of hydrolysis, and 
bioconversion can be affected by various factors such as age, health conditions and 
gender [35-37]. 
 
The classic prodrug approach was focused on altering various physiochemical 
parameters, whereas the modern computational approach, considers designing prodrugs 
through attaching appropriate linkers with drugs having poor bioavailability which upon 
exposure to physiological environments release the parent active drugs in a 
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programmable (controlled) manner resulting in an improvement of their bioavailability. 
With the possibility of designing prodrugs with different linkers, the release rate of the 
parent active drugs can be controlled [38]. 
 
 
1.2   Computational Approach 
Computational methods have been used for calculating molecular properties of ground 
and transition states in the areas of organic, bioorganic and medicinal chemists. 
Computational chemistry uses principles of computer science to assist in solving 
chemical problems. It uses also the theoretical chemistry results, combined with efficient 
computer programs in order to calculate the structures, physical and chemical properties 
of molecules. 
Currently, quantum mechanics (QM) such as ab initio, semi-empirical and density 
functional theory (DFT), and molecular mechanics (MM) are commonly being used and 
broadly known as reliable tools for predicting structure-energy calculations for drugs and 
prodrugs alike [45]. 
 
1.2.1 Quantum Mechanics (QM) 
Quantum mechanics (QM) is defined as the science that describes the behavior of 
electrons and thus of chemistry. It includes ab initio, semi-empirical and density 
functional theory (DFT). 
1.2.1.1 Ab initio Method 
Ab initio is a Latin term which means “''from the beginning'', this term is set to 
computations that are derived directly from theoretical principles with no inclusion of 
experimental data. This is considered as an approximate quantum mechanical 
calculations that are usually made from mathematical approximations [40]. Ab 
initio methods normally are sufficient only for small systems and are based entirely on 
theory from first principles.  
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Furthermore, the ab initio molecular orbital methods (QM) including HF, G1, G2, 
G2MP2, MP2 and MP3 are based on rigorous use of the Schrodinger equation with a 
number of approximations. The advantages that are accounted for the ab initio electronic 
structure methods that they can be made to converge to the exact solution, when all 
approximations are sufficiently small in magnitude and when the finite set of basic 
functions tends toward the limit of a complete set. The convergence is usually not 
monotonic, and sometimes the smallest calculation gives the best result for some 
properties. While the disadvantage of ab- initio methods is their enormous computational 
cost. They take a significant amount of computer time, memory, and disk space [41-45]. 
1.2.1.2 Semi-empirical Methods 
Semi empirical calculations have the advantage in that they are much faster than ab initio 
calculations with a disadvantage that the results can be erratic and fewer properties can be 
predicted consistently. If the molecule being computed is similar to molecules in the 
database used to parameterize the method, then the results may be very good. If the 
molecule being computed is significantly different from anything in the parameterization 
set, the answers (solutions) may be very poor [40]. 
Semi-empirical calculations have a Hamiltonian and a wave function and are set up with 
the same general structure as a Hartree-Fock (HF) calculation. Within this framework, 
certain pieces of information are approximated or completely omitted. Typically, only a 
minimal basis set is used and the core electrons are not included in the calculation. Also, 
some of the two-electron integrals are omitted. The method is parameterized to correct 
for the errors introduced by omitting part of the calculation. Parameters to estimate the 
omitted values are obtained by setting the results to experimental data or ab initio 
calculations. Often, these parameters replace some of the integrals that are excluded. 
Moreover, the most frequently used semi-empirical methods are MINDO, MNDO, 
MINDO/3, AM1, PM3 and SAM1. Calculations of molecules containing up to100 atoms 
(this number can be increased if super computers are utilized) can be handled using semi-
empirical methods [46, 47]. 
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1.2.1.3   Density Functional Theory (DFT) 
Density Functional Theory (DFT) has been developed more recently than other ab initio 
methods in order to investigate the electronic structure of many-body systems, 
specifically atoms, molecules, and molecules in the condensed phases (solid phase) [48]. 
With this method, the electron density can determine the energy of a molecule by using 
functions that is functions of another function.  
Still, this theory originated with a theorem by Hoe burg and Kohn and a practical 
application by Kohn and Sham. The original theorem was applied for the ground-state 
electronic energy of a molecule. However, the practical application of this theory was 
similar in structure to the Hartree-Fock method [49]. 
DFT has become very common in recent years because of the pragmatic observation that 
it is less computationally intensive than other methods with similar accuracy. Also, this 
method is sufficient for calculating structures and energies for medium-sized systems 
(30-60 atoms) of biological, pharmaceutical and medicinal interest and is not restricted to 
the second row of the periodic table. Although using the DFT method is significantly 
increasing some difficulties still encountered when describing intermolecular 
interactions, especially van deer Waals forces (dispersion); charge transfer excitations; 
transition states, global potential energy surfaces and some other strongly correlated 
systems. Incomplete treatment of dispersion can adversely affect the DFT degree of 
accuracy in the treatment of systems which are dominated by dispersion [48]. 
1.2.2 Molecular Mechanics 
The limited size of the molecule that can be modeled on even the largest computers is 
considered as the most severe limitation of ab initio methods. To illustrate, semi-
empirical calculations can be used for large organic molecules, a well they are too 
computation-intensive for most bimolecular systems. Besides, if a molecule is so big that 
a semi-empirical treatment cannot be used effectively, it is still possible to model its 
behavior avoiding quantum mechanics totally by using molecular mechanics [40]. 
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Molecular mechanics is a mathematical approach which is widely used in calculating 
many diverse biological and chemical systems such as proteins, large crystal structures, 
and relatively large solvated systems, it also used for the computation of structures, 
energy, dipole moment, and other physical properties. Though, this method is limited by 
the determination of parameters such as the large number of unique torsion angles present 
in structurally diverse molecules [50]. 
Molecular mechanics simulations use a single classical expression for the energy of a 
compound, for example, the harmonic oscillator. The database of compounds used for 
parameterization is crucial to the success of molecular mechanics calculations; for 
instance, the resulting set of parameters and functions is called the force field that  
parameterized against a specific class of molecules, for instance proteins, would be 
expected to only have relevance when describing other molecules of the same class. The 
applicable way for this method could be done on proteins and other large biological 
molecules, and allow studies of the approach and docking of potential drug molecules. 
Subsequently, the size of the system which ab initio calculations can handle is relatively 
small despite the large sizes of bio-macromolecules surrounding solvent water molecules 
such as in the cases of enzymes and receptors, isolated models of areas of proteins 
including active sites have been investigated using ab initio calculations. Though, the 
disregarded proteins and solvent surrounding the catalytic centers have also been shown 
to contribute to the regulation of electronic structures and geometries of the regions of 
interest. To overcome these inconsistencies, quantum mechanics/molecular mechanics 
(QM/MM) calculations are used, in that the system is divided into QM and MM regions 
where QM regions correspond to active sites to be studied and are described quantum 
mechanically. MM regions correspond to the remainder of the system and are treated 
molecular mechanically. The pioneer work of the QM/MM method was accomplished by 
Warshel and Levitt [51], and since then, there has been a significant progress on the 
development of a QM/MM algorithm and applications to biological systems [52,53]. 
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1.3   Dopamine 
3,4-Dihydroxyphenethylamine is a neurotransmitter that is naturally produced in the 
body. In the brain, it activates the five types of dopamine receptors– D1, D2, D3, D4, and 
D5. Dopamine is produced in several areas of the brain, including the substantial nigra 
and the ventral tegmental area [39]. Dopamine has the following chemical structure 
(Figure 1). 
 
OH
OHH2N  
 
Figure 1: Structural formula of dopamine 
 
Dopamine is also a neurohormone released by the hypothalamus, and its main task to act 
as a hormone is to inhibit the release of prolactin from the anterior lobe of the pituitary. 
Dopamine has several functions in the brain. It exists in the regions of the brain that 
regulate movement, emotion, motivation, and the feeling of pleasure. Shortage of 
dopamine, particularly the death of dopamine neurons in the nigrostriatal pathway, causes 
Parkinson’s disease, in which a person loses the ability to perform smooth, controlled 
movements [39]. 
 
Dopamine can be supplied as a medication that acts on the sympathetic nervous system, 
producing effects such as increased heart rate and blood pressure. However, because 
dopamine cannot cross the blood–brain barrier, dopamine given as a drug does not 
directly affect the central nervous system. To increase the amount of dopamine in the 
brains of patients with diseases such as Parkinson's disease and dopa-responsive dystonia, 
LD (levodopa), which is the precursor of dopamine, is given because it can cross the 
blood–brain barrier [39]. 
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Levodopa is typically co-administered with an inhibitor of peripheral decarboxylation 
[dopa decarboxylase (DDC)], such as carbidopa or benserazide [54, 55]. 
 
1.4  Parkinson’s disease 
Parkinsonism is a progressive neurological disorder of muscle movement that is 
manifested clinically by bradykinesia, tremor, rigidity, flexed posture, postural instability, 
and freezing of gait. It is characterized pathologically by the loss of pigmented 
dopaminergic neurons in the substantial nigra [56]. 
 
Although the exact cause of PD remains unknown, most cases are hypothesized to be a 
result of multiple factors acting together, including ageing, genetic susceptibility, and 
environmental exposures [57]. 
 
1.5   Problem Statement 
Patients with Parkinson’s disease have insufficient dopamine in specific regions of the 
brain, so attempts have been made to replenish the deficiency in the dopamine [58]. 
Unfortunately, peripherally administered (outside of the central nervous system) 
dopamine is not effective because it cannot cross the blood brain barrier. The reason for 
its inability to cross the BBB has to do with at least two influencing factors.  The first is 
that dopamine is a hydrophilic molecule which is expected to exist primary in the ionized 
forms (Figure 2) in a physiologic environment of pH 7.4 (blood circulation) resulting in a 
greater degree of difficulty in crossing cell membranes.  The second is the absence of a 
transporter for dopamine to pass the blood brain barrier into the brain [59]. 
 
 
 
 
Figure 2: Ionized form of dopamine at physiological environment 
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However, the precursor to dopamine, LD (Figure 3), was and still the best choice of 
treatment for this disease. LD is able to get into the brain via a large neutral amino acid 
carrier or L (leucine) system [60]. Once LD gets inside the brain it can then be 
metabolized by dopa decarboxylase or amino acid decarboxylase to form dopamine 
within the dopaminergic neurons within the substantia nigra [61].  
 
HO
HO
OH
O
NH2
 
 
Figure 3: Chemical structure of Levodopa 
Because much of the drug is decarboxylated to dopamine in the periphery, high doses of 
LD are required, resulting in side effects that include nausea, vomiting, cardiac 
arrhythmias, and hypotension [62]. These drawbacks of LD are the known reason of 
disability in PD patients [63, 64]. They can be explained according to this manner: In the 
normal brain the basal ganglia always maintained to satisfy the brain needs of dopamine 
for motor control and others, but LD oral administration have a low bioavailability of 
10% with only 1% of LD reaching the brain. This is due to the erratic gastrointestinal 
metabolism the drug faces before it attaches to the l-amino acid carrier that transports it 
actively through the duodenum where it enters the blood stream intact [65-70]. With the 
co-administration of either carbidopa or benserazide, an increase of LD bioavailability by 
two-fold was observed with only 5% to 10% of administered LD enters the brain [71, 
72].  As a result, lessened amounts of dopamine put the brain under fluctuations that are 
hard to accommodate [73, 74]. To minimize the conversion to DA outside the CNS, LD 
is usually given in combination with peripheral inhibitors of amino acid decarboxylase 
such as carbidopa or benserazide. In spite of that, other central nervous side effects such 
as dyskinesia, on-off phenomenon and end-of-dose deterioration still remain [75]. 
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The main factors responsible for the poor bioavailability and the wide range of inter- and 
intra-patient variations of plasma levels are the LD physicochemical properties such as 
low lipid solubility which resulted to unfavorable partition, and the high susceptibility to 
chemical and enzymatic degradation [76]. Starting from these considerations the prodrug 
approach has been applied to dopamine in order to overcome its metabolism problems 
and to improve its bioavailability. 
 
1.6   Thesis Objectives 
1.6.1 General Objective 
The main goal of this study was to design novel dopamine prodrugs for the treatment of 
Parkinson’s disease that have the potential for higher bioavailability than the current 
medications when given in different dosage forms and having the potential to release 
their parent drugs in a controlled manner, using a variety of different molecular orbital 
and molecular mechanics methods and correlations between experimental and calculated 
reactions rates. 
For achieving this goal, the dopamine prodrugs physicochemical properties must have the 
following: 
(i) To be soluble and stable in physiological environment. 
(ii) To have a moderate hydrophilic lipophilic balance (HLB) value. 
(iii) To provide upon chemical cleavage the parent drug in a controlled 
manner. 
(iv) To furnish upon cleavage a safe and non-toxic by-products. 
1.6.2 Specific Objectives 
Calculations of Kirby’s enzyme model mechanism for the design of dopamine prodrugs 
which should have the following properties: 
 A chemically driven sustained release system that releases the dopamine in a 
controlled manner. 
 The linker attached to the drug moiety and the whole dopamine prodrug moiety 
should have no toxicity and safe. 
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 A drug with a high bioavailability and efficient pharmacokinetic properties.  
 
1.7     Research Questions 
Would the DFT calculations be good methods for a design of Dopamine prodrugs that 
have the potential for higher bioavailability than the current medications when given in 
different dosage forms and be cleaved in physiological environments to furnish the active 
drugs and a non-toxic moiety? 
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2 Literature Review 
 
Literature reveals that many efforts have been made to synthesize prodrugs to improve 
bioavailability, decreased side effects, and potentially enhanced CNS delivery of the 
dopamine. 
 
2.1 Previous Attempts to Make Prodrugs of Dopamine 
 
2.1.1 Ester dopamine prodrugs 
Dopamine has poor permeation across the BBB and other cell membranes due to its 
complete ionization at physiological pH. Therefore, it cannot be used for PD [77].In order 
to resolve these problems, Casagrande et al. and Borgman et al. have prepared a number 
of lipophilic 3,4-O-diesters prodrugs of DA (Figure 4) as a latent lipophilic derivatives of 
DA to be used in the therapy of parkinsonism, hypertension and renal failure [77,78]. But 
the results showed that O-acetylation was not enough to provide entry into CNS while 
preservation intrinsic dopaminergic activity and N-alkylation of the DA molecule are also 
required. 
RCOO
RCOO
CH2CH2NH2
1. R = CH3
2. R = CH(CH3)2
3. R = C(CH3)3
4. R = C6H5
5. R = C2H5O  
 
Figure 4: A series of lipophilic 3,4-O diesters dopamine  pro-drugs. 
 
2.1.2 Chemical delivery systems 
To enhance the permeation of DA to central nervous system, chemical delivery systems 
(CDSs) have been established. These prodrug devices have been prepared by joining DA 
with a pyridinium/dihydropyridine redox carrier. A dihydropyridinium-type CDS is 
lipophilic enough to cross the membrane of CNS by passive transport and then undergoes 
an enzymatic oxidation to an ionic pyridinium precursor, this lead to locked compounds 
in the CNS [79]. CDS used also for brain-enhanced delivery of neurotransmitters, 
steroids, anticonvulsants, antibiotics, antiviral, anticancer, neuropeptides and their 
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analogs [79-81].This carrier enables the prodrug to cross BBB and then be oxidized to a 
quaternary precursor that is retained in the CNS, to provide a DA in a sustained release 
form (Figure 5). 
N
CH3
N
H
O
OCOCH3
OCOCH3
N
CH3
N
H
O
OCOCH3
OCOCH3
N
CH3
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H2N
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OH
Brain Oxidation
Hydrolysis
 
Figure 5: Dopamine delivery from pyridinium/dihydropyridine redox carrier system. 
 
The use of the dihydropyridine is actually restricted due to instability of its 5,6-double 
bond, which undergoes air-oxidation and/or hydration. This oxidation/hydrolysis reaction 
yields 6-hydroxy-1,4,5,6-tetrahydropyridine, which does not undergo enzymatic 
oxidation in vivo to give the corresponding quaternary pyridinium salt [82]. In order to 
overcome this problem, Carelli et al. suggest an interconvertible 
tetrahydrobipyridine/pyridinium salt (Figure 6) by irreversible dimerization of two 
pyridinyl radicals accomplish by one-electron electro-chemical reduction of pyridinium 
salts as nicotin-amide coenzymes or their models. In contrast with monomeric 
dihydropyridines, the tetrahydrobipyridines are more stable and easily oxidized back to 
the compound pyridinium salts by chemical oxidants or by oxygenase and peroxidase 
enzymes [81]. 
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Figure 6: Chemical structure of tetrahydrobipyridine. 
 
2.1.3 Peptide transport-mediated prodrugs 
2-Amino-N-[2-(3,4-dihydroxy-phenyl)-ethyl]-3-phenyl-propionamide (DOPH), an amide 
prodrug of DA, has been earlier proposed by Giannola et al. (Figure 7) [83]. It is 
synthesized by condensation of dopamine with a neutral amino acid to be able to interact 
with the BBB endogenous transporters and easily enter the brain. (DOPH) has the 
capacity to be slowly cleaved by cerebral enzyme (t½ 460 min) and produce free 
dopamine in the brain, but it undergoes a rapid hydrolysis in human plasma (t½ 28 min). 
Chemical stability studies on DOPH showed that no DA release occurred in the 
gastrointestinal tract and the prodrug was able to pass through a simulated intestinal 
mucosal membrane. 
 
HO
HO
HN
O
NH2
 
Figure 7: Chemical structure of 2-amino-N-[2-(3,4-dihydroxy-phenyl)-ethyl]-3-phenyl-
propionamide (DA-PHEN) 
 
In another study and in an attempt to enhance BBB permeability of dopamine, More and 
Vince focused on the glutathione uptake transporters that are located on the luminal side 
of the BBB. The broad substrate specificity displayed by these transporters provides vast 
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opportunity for rational prodrug design. The design of glutathione transporter targeted 
prodrug involved three components: the carrier, glutathione (GSH), the active drug, and a 
suitable linker for conjugation of the carrier with the drug molecule. The prodrug in 
(Figure 8) in which the dopamine is covalently linked via an amide bond to glutathione 
(GSH) showed high affinity for the GSH transporter at the BBB, released dopamine at 
the active site and possessed a good stability balance between the periphery and brain 
[84]. 
 
Figure 8: Chemical structure of the anti-Parkinson’s prodrug of dopamine. Shown in 
green is the carrier, metabolically stable glutathione analogue; in blue is the linker, 
mercaptopyruvic acid, and in red is the active drug moiety. 
 
N-3,4-bis(pivaloyloxy)-dopamine-3-(dimethylamino)propanamide (PDDP) (Figure 9), a 
brain specific derivative of dopamine, was designed and prepared, which consists of a 
brain targeted ligand, N,N-dimethyl amino group, and two dipivaloyloxy groups for 
lipophilic modification. Tissue distribution, brain bioavailability, and therapeutic efficacy 
of PDDP were evaluated and compared with L-DOPA and another brain dopamine 
prodrugs without N,N-dimethyl amino group which showed a more marked accumulation 
in rats brain microvascular endothelial cells than brain dopamine prodrugs through an 
active transport process. Following IV administration, the concentration of PDDP in the 
CNS was 269.28- and 6.41-folds higher than that of L-DOPA and brain dopamine 
prodrugs at 5 min, respectively. Therefore, PDDP would be a promising drug candidate 
that can be applied for targeted PD treatment [85]. 
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Figure 9: Chemical structure of N-3,4-bis(pivaloyloxy)-dopamine-3-
(dimethylamino)propanamide (PDDP) 
 
2.1.4 GLUT1 carrier-mediated prodrugs 
With the aim of overcoming the problem of the low BBB permeability of dopamine, a 
novel glycosyl derivatives of dopamine were synthesized which have the ability to be 
transported by GLUT1. Fernandez and coworkers described the synthesis and biological 
activities of several glycosyl derivatives of dopamine by conjugating sugar with 
dopamine through a succinyl linker, carbamate bond, glycosidic and ester bonds. They 
linked the amino group of dopamine to the C-6, C-3 and C-1 of the sugar through a 
succinyl linker or a carbamate bond. In another series, the sugar was linked to the 
phenolic groups of dopamine through a glycosidic bond and ester bonds. The affinity of 
these prodrugs for glucose carrier GLUT-1 using human erythrocytes was also tested [86, 
87]. When incubated with the brain extracts, the nature of the bond that links DA with 
glucose affected the rate in which the prodrug releases dopamine. The glycosyl 
conjugates substituted at the C-6 position of the sugar were more potent inhibitors of 
glucose transport in contrast to that of C-1 and C-3 substituted derivatives. From the 
studied compounds, the carbamate derivatives 9, 11 and 12 were the prodrugs of choice, 
in particular compound 9, which showed the best affinity for GLUT-1, even with higher 
affinity than glucose itself [88, 89]. 
In another study, Bonina et al. and Ruocco et al. have prepared dopamine glycoside 
prodrugs by attaching DA to C-3 position of glucose (19 in Figure 10) and to C-6 of 
galactose (20 in Figure 10) by a succinyl spacer. Pharmacological studies showed that 
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these two prodrugs were found to be more active than LD in reversing reserpine-induced 
hypo-locomotion in rats.  
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Figure 10: Chemical structures of glycosuccinyl-derivatives of dopamine. 
 
2.2 Enzyme Model 
Despite that some success has been obtained using the different strategies by which 
prodrugs of dopamine were used to supply dopamine in adequate concentrations and 
sustained release manner, the prodrugs chemical approach involving enzyme catalysis 
has many limitations related to many intrinsic and extrinsic factors that can affect the 
process. For example, the activity of many prodrug-activating enzymes may be varied 
due to genetic polymorphisms, age-related physiological changes, or drug interactions, 
causing variation in clinical effects [90-94]. 
Karaman’s group has explored a number of intra-molecular processes to gain insight into 
enzyme catalysis, toward the development of prodrug linkers that can be covalently 
attached to commonly used drugs which could have the potential for higher 
bioavailability over existing medications and would be chemically, and not 
enzymatically, be converted to release the active drugs in a controlled manner [95-130], 
by using ab-initio and density functional theory (DFT) molecular orbital methods. 
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2.2.1 Computationally Designed Dopamine Prodrugs Based on proton transfer 
reaction in some of Kemp’s acid amide derivatives 
Karaman’s group have been designed a number of dopamine prodrugs to be used in the 
treatment of Parkinson‘s disease with a higher bioavailability than the current medication. 
These designed prodrugs have the following physicochemical features: (i) owning 
moderate hydrophilic lipophilic balance (ii) soluble in physiological environment (iii) 
deliberate dopamine in a controlled manner, and (iv) undergo chemical cleavage to 
nontoxic by-products [59]. 
They explored the proton transfer reaction in some of Kemp’s acid amide derivatives by 
using enzyme models as potential linkers to be linked to amine-drugs [117]. Based on the 
DFT calculations on proton transfer mechanism of these acid amides, two dopamine 
derivatives were proposed. As shown in (Figure 11), ProD 32 and ProD 33 have a 
carboxylic group as a hydrophilic moiety and the rest of the prodrug as a lipophilic 
moiety, where the combination of both moieties secures a moderate HLB. Furthermore, 
at physiological pH in the blood circulation the expected predominant form of dopamine 
is the ionized form while its prodrug 32 and prodrug 33 are predicted to exist in the ionic 
and free acid forms. So, ProD 32 and ProD 33 may have a higher bioavailability than 
dopamine due to improved absorption. Also, the designed prodrugs can be used in many 
dosage form (e.g. enteric coated tablets) because they are  predicted to be soluble in 
organic and aqueous media due to the ability of the carboxylic group to be converted to 
the corresponding carboxylate anion in physiological environments of pH 5.0-7.4 
(intestine and blood circulation). 
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Figure 11: Dopamine prodrugs, ProD 32- ProD 33. 
 
2.2.2 Computationally Designed Prodrugs Based on Intramolecular Amide 
Hydrolysis of Kirby’s N-Alkylmaleamic Acids  
 
Kirby et al. studied the efficiency of intramolecular catalysis of amide hydrolysis by the 
carboxyl group of a number of substituted N-methylmaleamic acids and found that the 
reaction is remarkably sensitive to the pattern of substitution on the carbon–carbon 
double bond [132] . 
 
Karaman  et al. utilized N-alkylmaleamic acids as prodrug linkers for amine drugs such 
as, atenolol, acyclovir, cefuroxime, and other drugs, having poor bioavailability or/and 
undesirable (bitter) taste, and have unraveled the mechanism for the acid-catalyzed 
hydrolysis using DFT and molecular mechanics methods [113-115, 131]. 
 
Based on the DFT calculation results on the acid-catalyzed hydrolysis of N-
alkylmaleamic acids [132], acyclovir [113], atenolol [114] and cefuroxime [115] several 
prodrugs were designed and the reactions of the intraconversion of the designed prodrugs 
into the parent drugs were computationally studied. The prodrugs are composed of the 
carboxylic acid amide linker having a carboxylic acid group (hydrophilic moiety) and the 
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rest of the prodrug molecule (a lipophilic moiety). The combination of both groups 
secures a prodrug moiety with a potential to have high permeability (a moderate HLB). 
So as I mentioned previously this approach was utilized by Karaman et al, to achieve 
desirable acyclovir, atenolol and cefuroxime prodrugs that are capable of being stable in 
aqueous solutions, more lipophilic, less bitter (cefuroxime and atenolol) and to have the 
potential to release the corresponding drugs in a slow release manner. 
 
It is worth noting that all of the developed techniques for enhancing the bioavailability of 
active ingredients are based on design prodrugs so that they undergo cleavage in 
physiologic environments via enzyme catalysis and/or via in vivo chemical reactions. But 
Karaman's approach is a novel chemical approach involves a design of prodrugs for 
enhancing bioavailability of pharmaceuticals based on intramolecular processes using 
density functional theory (DFT) and ab initio methods and correlations of experimental 
and calculated reactions rates. No enzyme is needed to catalyze the interconversion of a 
prodrug to its corresponding drug. 
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3. Computational (Design) section 
 
Calculation programs and methods used in the thesis 
3.1 Calculation programs: 
 
The following programs were exploited in the design calculations: 
3.1.1 Arguslab 
3.1.2 Gausian2009 
3.1.3 Molden 
 
3.1.1 Arguslab: 
Arguslab is considered as a molecular modeling, drug and graphics design program that 
offers a moderate library of useful molecules, with quite good on-screen molecule-
building facilities and it is a free downloaded program. Furthermore, it can do geometry 
optimizations using the UFF force field that covers all elements of the Periodic Table 
because it is not restricted to known atom types in its parameterization, though it does use 
some common ones.  The resulting energies of this program are clearly disguisable from 
those obtained using some of the more conventional force fields, and wherever possible 
one needs to re-optimize at a higher level.  Consequently, Arguslab offers single point 
calculations, as well as geometry optimization using the MNDO, AM1 or PM3 semi-
empirical methods.  There are also single point semi-empirical calculations using ZINDO 
(for excited states for UV/visible absorption prediction) or Extended Huckel (for a bigger 
element coverage).  Version 3.1 of Arguslab has good facilities for calculating electron 
density or orbital surfaces at the semi-empirical levels, and displaying them also [133]. 
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Arguslab writes its own format of molecule file, like .xml, but it can also write xyz files 
for input to other programs, e.g. Molden.  It creates (and leaves behind) a lot of 
temporary files, which need to be managed.  
To start work using Arguslab free program the users have two choices, they can press the 
'New' button (top left) to get a new molecule screen, or press the 'Open' button to read in 
a molecule which has saved previously in the Argus directory.  
Besides, using the Arguslab the users can save their molecule with whatever name they 
want before doing a geometry optimization as well as afterwards. Accordingly, all the 
additional files will have the right names and if they forget to change the file name before 
modifying a molecule, files will be saved automatically with the name used previously, 
possibly destroying data which they wanted to keep. It is best not to maximize the 
molecule window, because then its title bar will display the name by which we are 
currently saving the files. Just drag its bottom right corner so that it fills most of the 
Arguslab worktop. To stop using Argus lab, click File Exit, if we have molecule windows 
open, this will just close one of these.  The users need to do it repeatedly to close all the 
windows (if they have several open) and then stop the program. 
3.1.2   Gausian 2009 
There are many versions of the Gaussian series of computer program for computational 
chemistry and Gaussian 09 is the latest version that is designed to model a broad range of 
molecular systems under a variety of conditions and perform its computations starting 
from the basic laws of quantum mechanics. Both theoretical chemists and experimental 
chemists can use Gaussian 09, to illuminate, theoretical chemists uses it to perform basic 
research in established and emerging areas of chemical interest whereas experimental 
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chemists can use it to study molecules and reactions of definite or potential interest, as 
well as stable species and those compounds which are difficult or impossible to observe 
experimentally such as short-lived intermediates, transition structures and so on) [134]. 
Another work for Gaussian 09 is that it can it can model both their ground state and 
excited states and it can also predict energies, molecular structures, vibration frequencies 
and numerous molecular properties for systems in the gas phase and in solution.  
Moreover, there are different levels that can be run using Gaussian 09 installed on PC, a 
computer station or computer server; for example,  AM1, PM3, MINDO/3, MNDO, HF, 
DFT, MP2 and MP3 . 
Using the Gaussian 09 the input files can be created in two ways: by hand using a local 
editor (VI, emacs and nedit) or by using Molden. And to view output files from files run 
in Gaussian 09, input files for use in Gaussian 09 can be generated using Molden 
program. Finally, dissecting the output file in that the Z-matrix represents how the 
software knows the molecular geometry (structure). Notice that the molecule has no 
charge and a multiplicity of 1 (all paired electrons). The structure is also represented as a 
more standard xyz coordinate system. The distance matrix shows the distance of each 
atom from the other atoms, in units of angstroms. 
 
3.1.3 Molden: 
 
Molden is a computational program package that can interpret and convert information 
from the ab-initio packages, Games-US, Games-UK and Gaussian, as well as 
Mopac/Ampac programs into its own format, and it made for displaying molecular 
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densities from these programs. Furthermore, the benefit of using this programs format is 
simple. It can also be used as a visual Z-matrix molecule editor, thereby allowing users to 
create the molecule of their choice and being able to save the geometry in the Molden 
format [135]. Molden format incorporates numerous data stores in a text file; each piece 
of data is headed by a key term e.g. [MO] for molecular orbitals, [STO] for slater type 
orbital basis sets, plus many others like [GTO],[GEOMETRIES] etc.  It also supports 
contour plots, 3-d grid plots with hidden lines and a combination of both. It can write a 
variety of graphics instructions; postscript, X-Windows, VRML, povray, OpenGL, 
tekronix4014 and hpgl, hp2392. Moreover, this format can animate reaction paths and 
molecular vibrations. It can calculate and display the true or multipole derived 
electrostatic potential and atomic charges can be fitted to the electrostatic potential 
calculated on a Connolly surface. Molden has a powerful Z-matrix editor which gives full 
control over the geometry and allows building molecules from scratch, including 
polypeptides. It also features a stand-alone force field program ambfor, which can 
optimize geometries with the combined Amber (protein) and GAFF (small molecules) 
force fields. Atoms type can be done automatically and interactively from within Molden, 
as well as firing optimization jobs. 
 
3.2    Calculation methods: 
In our calculations, the Becke three-parameter, hybrid functional combined with the Lee, 
Yang, and Parr correlation functional, denoted B3LYP, were employed using density 
functional theory (DFT). All calculations were carried out using the quantum chemical 
package Gaussian-2009 [136].   
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Calculations were carried out based on the restricted Hartree-Fock method [136]. The 
starting geometries of all calculated molecules were obtained using the Argus Lab 
program [137]  and were initially optimized at the HF/6-31G level of theory, followed by 
optimization at the B3LYP/6-31G(d,p). Total geometry optimizations included all 
internal rotations. Second derivatives were estimated for all 3N-6 geometrical parameters 
during optimization. The search for the global minimum structure in each of the systems 
studied was accomplished by 36 rotations of the carboxyl group about the bond C4-C6 in 
increments of 10° (i.e. variation of the dihedral angle O5C4C6C7, see Chart 1) and 
calculation of the energies of the resulting conformers. 
An energy minimum (a stable compound or a reactive intermediate) has no negative 
vibrational force constant. A transition state is a saddle point which has only one negative 
vibrational force constant [138]. Transition states were located first by the normal 
reaction coordinate method [139] where the enthalpy changes were monitored by 
stepwise changing the interatomic distance between two specific atoms. The geometry at 
the highest point on the energy profile was re-optimized by using the energy gradient 
method at the B3LYP/6-31G (d, p) level of theory [136]. The “reaction coordinate 
method” [139] was used to calculate the activation energy in dopamine ProD 1- ProD 5 
(Figures 15 - 17).  
In this method, one bond length is constrained for the appropriate degree of freedom 
while all other variables are freely optimized. The activation energy values for the proton 
transfer processes (transfer of H7 from O6 into O1, Chart 1) were calculated from the 
difference in energies of the global minimum structures (GM) and the derived transition 
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states. Verification of the desired reactants and products was accomplished using the 
“intrinsic coordinate method” [83]. The transition state structures were verified by their 
only one negative frequency. Full optimization of the transition states was accomplished 
after removing any constrains imposed while executing the energy profile. The activation 
energies obtained from the DFT at B3LYP/6-31G (d,p) level of theory for all molecules 
were calculated in a gas phase and water phase. The calculations with the incorporation 
of a solvent were performed using the integral equation formalism model of the 
Polarizable Continuum Model (PCM) [140-143]. In this model, the cavity is created via a 
series of overlapping spheres. The radii type employed was the United Atom Topological 
Model on radii optimized for the PBE0/6-31G (d) level of theory. 
 
 
Chart 1: Schematic representation of the reactants in the proton transfers of dopamine 
ProD 1-ProD 5. GM is the global minimum structure, rGM is the O—H distance in the 
GM. α, is the angle of attack (hydrogen bonding) O1-H2-O3 in the GM. 
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4. Results and Discussion 
Acid-catalyzed hydrolysis of N-alkylmaleamic acids 1-7 (Figure 12) was kinetically 
studied by Kirby’s group; they concluded that the amide bond cleavage occurs due to 
intramolecular nucleophilic catalysis by the adjacent carboxylic acid group and the rate-
limiting step is the tetrahedral intermediate breakdown [144]. 
 
Figure 12: Acid-catalyzed hydrolysis of N-alkylmaleamic acids. 
DFT calculations on the acid-catalyzed hydrolysis of Kirby`s N-alkylmaleamic acids that 
were done by Karaman’s group showed that the rate limiting step in aqueous medium is 
the collapse of the tetrahedral intermediate  whereas in the gas phase the rate limiting step 
is the formation of the tetrahedral intermediate. Furthermore, Karaman’s calculations 
revealed a correlation between the acid-catalyzed hydrolysis efficiency and the following 
parameters: 
1. The difference between the strain energies of intermediate and product and 
intermediate and reactant.  
2. The distance between the hydroxyl oxygen of the carboxylic group and the amide 
carbonyl carbon. 
3. The attack angle.  
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The calculations also demonstrated that the acid catalyzed reaction involves three steps: 
(1) proton transfer from the carboxylic group to the adjacent amide carbonyl oxygen, (2) 
nucleophilic attack of the carboxylate anion onto the protonated carbonyl carbon; and (3) 
dissociation of the tetrahedral intermediate to provide products (Figure 13). 
 
Figure :13  Proposed mechanism for the acid-catalyzed hydrolysis of N-alkylmaleamic 
acids. 
 
Based on the calculation results of Kirby`s model (proton transfer in N-alkylmaleamic 
acids) we proposed some prodrugs of dopamine by linking this drug with anhydride 
linker such as maleic, succinic, dimethylmaleic, 1,2-cyclohexanedicarboxylic and 
hexahydro-4-methylphthalic (Figure 14) in order to: (1) improve the bioavailability of the 
parent drugs, (2) to make a chemical device that is capable of releasing the parent drug in 
a sustained release manner. 
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As shown in Figure 14, Dopamine ProD 1- ProD 5 have a carboxylic group (hydrophilic 
moiety) and a lipophilic moiety (the rest of the prodrug), where the combination of both 
moieties secures a modified HLB. 
                 
 
                        
Figure 14: Structural formula of the proposed dopamine prodrugs. 
 
The main advantage of Karaman’s proposed prodrugs is their ability to release the drug 
via chemical cleavage in a controlled manner depending on nature of the linker. 
So the aim of this work was to design various dopamine prodrugs by replacing the N-
methyl amide group in 1–7 (Figure 12) with dopamine drug, as shown for ProD 1-ProD 
5 in Figure 14. 
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In this section, we report DFT at B3LYP 6-31G (d,p) level calculations of ground state 
and transition state structures, vibrational frequencies, and reaction trajectories for 
intramolecular proton transfer in dopamine prodrugs ProD 1- ProD 5. 
 
Computations were directed toward elucidation of the transition and ground state 
structures (global minimum, intermediates and products) for the acid-catalyzed 
hydrolysis of dopamine  ProD 1– ProD 5 in the gas phase and in water phase (a 
dielectric constant of 79.38). It is expected that the stability of the chemical entities (GM, 
TS and P.) will be different in the gas phase compared to that in water (a relatively high 
dielectric constant). 
 
4.1 General Consideration 
Because the energy of a carboxylic acid amide molecule is strongly dependent on its 
conformation and the latter determines its ability to be engaged in intramolecular 
hydrogen bonding, we were concerned with the identification of the most stable 
conformation (global minimum) for each of prodrugs ProD 1– ProD 5 calculated in this 
study. This was accomplished by 360° rotation of the carboxylic group about the bond 
C6-C7 (i.e., variation of the dihedral angle O1C7C6C5, Chart 1), and 360° rotation of the 
carbonyl amide group about the bond C4-C5 (i.e., variation of the dihedral angle 
O3C4C5C6) in increments of 10° and calculation of the conformational energies (see 
Chart 1). 
 
In the DFT calculations for dopamine ProD 1– ProD 5, two types of conformations in 
particular were considered: one in which the amide carbonyl is syn to the carboxyl group 
and another in which it is anti. The global minimum search for dopamine ProD 1- ProD 
5 revealed that ProD 1, ProD 2, ProD 4 and ProD 5 exist in the syn orientation while 
ProD3 exists in the anti orientation (Figure 15). 
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4.2 Optimized geometries of the entities involved in the proton transfers 
of dopamine ProD 1- ProD 5. 
4.2.1 Global minimum geometries (GM): 
The calculated B3LYP/6-31 G (d,p) geometries along with selected bond distances and 
bond angles for the global minimum structures of ProD 1GM-5GM are illustrated in 
Figure 15. 
Examination of the calculated geometries of ProD 1GM-5GM (Figure 15) indicates that 
ProD 1 and ProD 2 exhibit conformation by which the carboxyl group is engaged 
intramolecular in a hydrogen bond with the neighboring amide oxygen. 
The calculated B3LYP/6-31 G (d,p) intramolecular hydrogen bonding length (rGM in 
Chart 1) in ProD 1GM and ProD 2GM was found in the range of 2.90Å −3.03Å and that 
for the hydrogen bond angle α (the hydrogen bond angle, O1H2O3 in Chart 1) in the 
range of 137.4°-128.8°. 
Inspection of the optimized structures for ProD 3GM-5GM indicates that the calculated 
DFT values for the intermolecular distance (rGM in Chart 1) range between 4.11Å and 
5.89Å, while the angle α was found in the range 23.1°- 61.3°. 
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Figure 15: DFT optimized structures for the global minimum (GM) structures in the 
intramolecular proton transfer reaction of dopamine ProD 1-ProD 5. 
 
4.2.2 Transition state geometries (TS): 
The calculated properties for the transition state geometries of Pro D1-Pro D5 ( ProD 
1TS-ProD 5TS) are summarized in Table 1 and illustrated in Figure16. 
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Figure 16: DFT optimized structures for the transition state (TS) structures in the 
intramolecular proton transfer reaction of dopamine ProD 1-ProD 5. 
 
4.2.3 Product geometries (P): 
The calculated properties for the product geometries of Pro D1-Pro D5 (ProD 1P-ProD 
5P) are summarized in Table 1 and illustrated in Figure17. 
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Figure 17: DFT optimized structures for the product (P) structures in the intramolecular 
proton transfer reaction of dopamine ProD 1-ProD 5. 
 
4.3 DFT calculations of the kinetic and thermodynamic energies for the proton 
transfer reaction in dopamine ProD1- ProD5. 
Using the quantum chemical package Gaussian-2009 [136] we calculated the DFT at 
B3LYP/6-31 G (d,p) level of theory kinetic and thermodynamic properties for all entities 
involved in the hydrolysis (global minimum structures (GM), transition states (TS) and 
products (P). The enthalpy and entropy energy values for all entities were calculated in 
the gas phase and cluster of water. 
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Table 1 lists the energy values for dopamine ProD 1GM – ProD 5GM dopamine ProD 
1TS – ProD 5TS and dopamine ProD 1P – ProD 5P, and Figures 15 - 17 show their 
DFT optimized structures, respectively. 
Using the calculated DFT values for the enthalpy and entropy of the global minimum 
structures of dopamine ProD 1-ProD 5 and their corresponding transition states (Table 1) 
we have calculated the enthalpy activation energies (ΔH‡), entropy activation energies 
(TΔS‡), and the free activation energies in the gas phase and water phase (ΔG‡) for the 
proton transfer reaction in these processes. The calculated energies are listed in Table 2. 
 
Table 1: DFT (B3LYP) calculated properties for the proton transfer reactions of in 
dopamine ProD1- ProD5. 
Compound 
B3LYP, Enthalpy, H 
(gas phase) in Hartree 
B3LYP (gas phase) 
Entropy, S, 
Cal/Mol-Kelvin 
B3LYP 
Frequency 
Cm-1 
Dopamine  ProD 1GM -895.9897836 138.243 ------- 
Dopamine  ProD 1TS -895.9363582 130.648 -196.447 
Dopamine  ProD 2GM -974.6348381 156.577 ------- 
Dopamine  ProD 2TS -974.5908693 149.1 -114.636 
Dopamine  ProD 3GM -897.2366718 147.57 ------- 
Dopamine  ProD 3TS -897.1765335 133.033 -64.076 
Dopamine  ProD 4GM -1053.276895 161.519 ------- 
Dopamine  ProD 4TS -1053.228622 150.338 -46.434 
Dopamine  ProD 5GM -1092.59478 168.32 ------- 
Dopamine  ProD 5TS -1092.544031 157.15 -44.925 
B3LYP refer to values calculated by B3LYP/6-31G (d, p). (GM) and (TS) are global 
minimum and transition state structures, respectively.  
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Table 2: DFT (B3LYP/6-31G (d,p) calculated kinetic and thermodynamic properties for 
the proton transfers in dopamine ProD 1-ProD  5. 
System 
 
∆H‡ 
(GP) 
TΔS‡ 
(GP) 
∆G‡ 
(GP) 
∆H‡ 
(H2O) 
∆G‡ 
(H2O) 
DopamineProD1 33.52459878 -2.255715 35.78031378 33.74416208 36.81662708 
DopamineProD2 27.59055391 -2.220669 29.81122291 30.81535457 33.03602357 
DopamineProD3 37.73696366 -4.317489 42.05445266 40.88658947 45.20407847 
DopamineProD4 30.29145232 -3.320757 33.61220932 33.71209667 37.03285367 
DopamineProD5 31.8449615 -3.31749 35.1624515 35.47287009 38.79036009 
 
4.3.1   The role of the distance O3-H2 (rGM) and the angle O1H2O3 (α) on the rate of 
the proton transfer in processes dopamine ProD 1- ProD 5. 
 
Table 2 indicates that the distance between the two reactive centers rGM (O1-H7) varies 
according to the conformation of the global minimum structure (GM). Short rGM distance 
values were achieved when the values of the attack angle (α) in the GM conformations 
were high and close to 180°, whereas small values of α resulted in longer rGM distances. 
In fact when the rGM values were plotted against the corresponding α values linear 
correlation was obtained with R2 = 0.9074 (Figure 18). In addition, examination of the 
activation energy values (∆G‡) listed in Table 2  reveals that the energy needed to execute 
proton transfer in systems dopamine ProD 1- ProD 5 is largely affected by both the 
distance between the two reactive centers rGM (O3-H2), and the attack angle α 
(O1H2O3). Systems with low rGM and high α values in their global minimum structures, 
such as ProD 1 and ProD 2, exhibit much higher rates (lower ∆G‡) than these with high 
rGM and low α values, such as ProD 3-ProD 5. 
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Figure 18: Plot of the DFT calculated rGM (Å) vs. angle α (°) in dopamine ProD 1-ProD 
5, where (rGM) and (α) are the distance between the two reactive centers and the attack 
(hydrogen bond) angle in the GM structure, respectively. 
 
When rGM and α values were examined for correlation with the water calculated DFT 
activation free energies (∆G‡), a linear correlation was found between ∆G‡ and rGM x 
(1/α) with a correlation coefficient of R2= 0.8835 (Figure 19). On the other hand, a 
correlation of the activation free energies (∆G‡) with rGM2 gave an R2 value of 0.8832, 
and with rGM gave an R
2 value of 0.8517. 
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Figure 19: Plot of the DFT calculated ∆G‡ vs. rGM  x (1/α) in dopamine ProD 1-ProD 5 
4.3.2   The role of the strain energy of the intermediates (EsINT) on the rate of the 
proton transfer in processes dopamine ProD 1- ProD 5. 
 
We calculated, using Allinger’s MM2 method [145], the strain energy values for the 
intermediates (EsINT) in process dopamine ProD 1-PoD 5 to examine the role of the 
(EsINT) on the rate of the proton transfer in process dopamine ProD 1-PoD 5. 
 
The MM2 strain energies of the intermediates are listed in (Table 3). The calculated 
MM2 (EsINT) values for the process dopamine ProD 1-PoD 5 were examined for 
correlation with the calculated DFT activation free energies (∆G‡), a linear correlation 
was found between ∆G‡ and EsINT with a correlation coefficient of R2= 0.9414 (Figure 
20). 
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Table 3: DFT (B3LYP) calculated kinetic and thermodynamic properties for the acid 
catalyzed hydrolysis of 1-7 N-alkylmaleamic acid and dopamine ProD 1- ProD 5 
System ∆G‡H2O (kcal/mol) EsINT log krel  
[146] 
 
1 33.06 20.55 0 
2 20.05 16.16 4.371 
3 28.42 17.32 1.494 
4 38.11 27.89 -4.377 
5 23.12 19.25 2.732 
6 27.28 17.59 1.516 
7 27.55 18.55 1.648 
ProD 1 36.82 9.24 ------ 
ProD 2 33.04 4.85 ------ 
ProD 3 45.20 -1.30 ------ 
ProD 4 37.03 8.75 ------ 
ProD 5 38.79 9.47 ------ 
 
 
 
 
Figure 20: Plot of the DFT calculated ∆G‡ vs. EsINT in dopamine ProD 1-ProD 5 
y = 1.0655x + 27.812
R² = 0.9146
32
33
34
35
36
37
38
39
40
0 2 4 6 8 10
∆
G
‡
EsINT
∆G‡ vs EsINT
46 
 
 
Examination of Figure 20 and Table 3 reveals that the rate of a proton transfer in 
processes dopamine ProD 1- ProD 5 is largely dependent on the strain energy of the 
tetrahedral intermediate. Systems having strained tetrahedral intermediates were found to 
be with low rates and vice versa. 
In order to further support this conclusion, the B3LYP 6-31G (d,p) activation energy 
values for 1-7 N-alkylmaleamic acid calculated in water (∆G‡H2O, see Table 3) were 
examined for correlations with log krel (relative rate) and the results are shown in (Figure 
21). A linear correlation was found between ∆G‡H2O  and log krel with a correlation 
coefficient of R2= 0.9303. 
Furthermore, a linear correlation was found between the strain energies for intermediates 
of 1-7 N-alkylmaleamic acid (EsINT) and log krel (Figure 22) with a correlation coefficient 
of R2= 0.885. 
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Figure 21: Plot of the DFT calculated ∆G‡ vs. relative rate (log krel) in 1-7 N-alkylmaleamic 
acid. 
 
 
Figure 22: Plot of the EsINT for intermediates of 1-7 N-alkylmaleamic acid vs. relative rate 
(log krel). 
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5. Conclusions and future directions 
 
5.1 Conclusions 
Based on the DFT calculations results of Kirby`s enzyme model (proton transfer in N-
alkylmaleamic acids), novel dopamine prodrugs for the treatment of Parkinson’s disease 
that can improve the overall biopharmaceutical profile of the current medications to 
enhance effectiveness and to ease the use of the medications were designed. 
The designed dopamine prodrugs have a carboxylic group as a hydrophilic moiety and a 
hydrocarbon skeleton as a lipophilic moiety, where the combination of both groups 
ensures a modified hydrophilic lipophilic balance value. 
DFT calculations were made to find a candidate to be used as an efficient dopamine 
prodrug. The DFT calculation results revealed that the rate of a proton transfer in 
processes dopamine ProD 1- ProD 5 is largely dependent on the geometric variations of 
the reactant (GM) mainly the distance between the two reactive centers, rGM, and the 
angle of attack α. It was found that systems with low rGM and high α values in their global 
minimum structures, such as ProD 1 and ProD 2, exhibit much higher rates (lower ∆G‡) 
than these with high rGM and low α values, such as ProD 3-ProD 5. 
Moreover, it was found that the rate of a proton transfer in processes dopamine ProD 1- 
ProD 5 is largely dependent on the strain energy of the tetrahedral intermediate. Systems 
having strained tetrahedral intermediates were found to be with low rates and vice versa. 
Therefore, I conclude that the best candidate to fulfill the requirements needed to reach 
better bioavailability than the parent dopamine is dopamine ProD 1 and ProD 2. 
 
5.2 Future directions 
Our future directions are (i) to synthesize dopamine ProD 1 and ProD 2 using Kirby’s 
synthetic procedure [12]. (ii) In vitro kinetic studies at different pH values should be 
made in order to be utilized for the in vivo pharmacokinetic studies which should be 
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followed to determine the t1/2 values for the conversion of the dopamine ProD 1 and  
ProD 2  to their parent drug, dopamine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
51 
 
 
References 
[1] Jana, S., Mandlekar, S., & Marathe, P. (2010). Prodrug design to improve 
pharmacokinetic and drug delivery properties: challenges to the discovery 
scientists. Current medicinal chemistry, 17(32), 3874-3908. 
[2] Han, H. K., & Amidon, G. L. (2000). Targeted prodrug design to optimize drug 
delivery. AAPS PharmSci, 2(1), 48-58. 
[3] Albert, A. (1958). Chemical aspects of selective toxicity. Nature, 182(4633), 421. 
[4] Higuchi, T., & Stella, V. (Eds.). (1975). Pro-drugs as novel drug delivery systems. 
American Chemical Society. 
[5] Stella, V., Borchardt, R., Hageman, M., Oliyai, R., Maag, H., & Tilley, J. (Eds.). 
(2007). Prodrugs: challenges and rewards. Springer Science & Business Media. 
[6] Stella, V. J., Charman, W. N. A., & Naringrekar, V. H. (1985). Prodrugs. Drugs, 
29(5), 455-473. 
 
[7] Banerjee, P. K., & Amidon, G. L. (1985). Design of prodrugs based on enzymes-
substrate specificity. Design of Prodrugs. New York: Elsevier, 93-133. 
 
[8] Müller, C. E. (2009). Prodrug approaches for enhancing the bioavailability of drugs 
with low solubility. Chemistry & Biodiversity, 6(11), 2071-2083.  
 
[9] Ettmayer, P., Amidon, G. L., Clement, B., & Testa, B. (2004). Lessons learned from 
marketed and investigational prodrugs. Journal of medicinal chemistry,47(10), 2393-
2404. 
[10] Stella, V. J., & Nti-Addae, K. W. (2007). Prodrug strategies to overcome poor water 
solubility. Advanced drug delivery reviews, 59(7), 677-694. 
[11] Fleisher, D., Bong, R., & Stewart, B. H. (1996). Improved oral drug delivery: 
solubility limitations overcome by the use of prodrugs. Advanced drug delivery 
reviews, 19(2), 115-130. 
[12] Menger, F. M., & Ladika, M. (1990). Remote enzyme-coupled amine release. The 
Journal of Organic Chemistry, 55(10), 3006-3007. 
[13] Huttunen, K. M., Raunio, H., & Rautio, J. (2011). Prodrugs—from serendipity to 
rational design. Pharmacological reviews, 63(3), 750-771. 
[14] Kadam, V. B., Dhanawade, K. B., Salunkhe, V. A., & Ubale, A. T. (2014). 
Prodrugs: A New Approach to Drug Design & its Applications. 
52 
 
 
[15] Liederer, B. M., & Borchardt, R. T. (2006). Enzymes involved in the bioconversion 
of ester‐based prodrugs. Journal of pharmaceutical sciences,95(6), 1177-1195. 
[16] Taylor, M. D. (1996). Improved passive oral drug delivery via prodrugs.Advanced 
drug delivery reviews, 19(2), 131-148. 
[17] Di, L., & Kerns, E. H. (2015). Drug-like properties: concepts, structure design and 
methods from ADME to toxicity optimization. Academic Press. 
[18] Karaman, R. (2014). Prodrugs for Masking the Bitter Taste of Drugs.Application of 
Nanotechnology in Drug Delivery, 399-445. 
[19] Brocks, D. R. (1999). Anticholinergic drugs used in Parkinson’s disease: an 
overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharm Sci, 2(2), 
39-46. 
[20] Kwan, K. C. (1997). Oral bioavailability and first-pass effects. Drug metabolism and 
disposition, 25(12), 1329-1336. 
[21] Chu, W. W. (1987). PROD RUG STRATEGIES FOR BYPASSING THE FIRST· 
PASS METABOLISM OF PROPRANOLOL (Doctoral dissertation, The University of 
Utah). 
[22]  Pardridge, W. M. (2007). Blood–brain barrier delivery. Drug discovery today,12(1), 
54-61. 
[23] Sozio, P., Cerasa, L. S., Abbadessa, A., & Di Stefano, A. (2012). Designing 
prodrugs for the treatment of Parkinson's disease. Expert opinion on drug discovery, 7(5), 
385-406. 
[24] Begley, D. J., & Brightman, M. W. (2003). Structural and functional aspects of the 
blood-brain barrier. In Peptide transport and delivery into the central nervous system (pp. 
39-78). Birkhäuser Basel. 
[25] Pardridge, W. M. (2001). Brain drug targeting: the future of brain drug 
development. Cambridge University Press. 
[26] Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006). Astrocyte–endothelial 
interactions at the blood–brain barrier. Nature Reviews Neuroscience, 7(1), 41-53. 
[27] Malakoutikhah, M., Teixidó, M., & Giralt, E. (2011). Shuttle‐Mediated Drug 
Delivery to the Brain. Angewandte Chemie International Edition, 50(35), 7998-8014. 
[28] Oprea, T. I., & Gottfries, J. (1999). Toward minimalistic modeling of oral drug 
absorption. Journal of Molecular Graphics and Modelling, 17(5), 261-274. 
[29] Fischer, H., Gottschlich, R., & Seelig, A. (1998). Blood-brain barrier permeation: 
molecular parameters governing passive diffusion. The Journal of membrane 
biology, 165(3), 201-211. 
53 
 
 
[30] Bodor, N., & Buchwald, P. (1999). Recent advances in the brain targeting of 
neuropharmaceuticals by chemical delivery systems. Advanced drug delivery 
reviews, 36(2), 229-254. 
[31] Bodor, N., & Buchwald, P. (2002). Barriers to remember: brain-targeting chemical 
delivery systems and Alzheimer's disease. Drug discovery today,7(14), 766-774. 
[32] Ohtsuki, S., & Terasaki, T. (2007). Contribution of carrier-mediated transport 
systems to the blood–brain barrier as a supporting and protecting interface for the brain; 
importance for CNS drug discovery and development.Pharmaceutical research, 24(9), 
1745-1758. 
[33] Tamai, I., & Tsuji, A. (2000). Transporter‐mediated permeation of drugs across the 
blood–brain barrier. Journal of pharmaceutical sciences, 89(11), 1371-1388. 
[34] Anderson, B. D. (1996). Prodrugs for improved CNS delivery. Advanced drug 
delivery reviews, 19(2), 171-202. 
[35] Moser, V. C., Chanda, S. M., Mortensen, S. R., & Padilla, S. (1998). Age-and 
gender-related differences in sensitivity to chlorpyrifos in the rat reflect developmental 
profiles of esterase activities. Toxicological sciences, 46(2), 211-222. 
[36] Draganov, D. I., & La Du, B. N. (2004). Pharmacogenetics of paraoxonases: a brief 
review. Naunyn-Schmiedeberg's archives of pharmacology, 369(1), 78-88. 
[37] Ngawhirunpat, T., Kawakami, N., Hatanaka, T., Kawakami, J., & Adachi, I. (2003). 
Age dependency of esterase activity in rat and human keratinocytes.Biological and 
Pharmaceutical Bulletin, 26(9), 1311-1314. 
[38] Karaman, R. Prodrugs (2014)-Current and Future Drug Development Strategy. Drug 
discovery, 1, 11. 
[39] Iversen, L. L. (2010). Dopamine handbook. Oxford University Press, USA. 
 
[40] Young, D. (2004). Computational chemistry: a practical guide for applying 
techniques to real world problems. John Wiley & Sons. 
 
[41] Testa, B. (2004). Prodrug research: futile or fertile?. Biochemical pharmacology, 
68(11), 2097-2106. 
 
[42] Ueda, Y., Mikkilineni, A. B., Knipe, J. O., Rose, W. C., Casazza, A. M., & Vyas, D. 
M. (1993). Novel water soluble phosphate prodrugs of Taxol® possessing in vivo 
antitumor activity. Bioorganic & Medicinal Chemistry Letters, 3(8), 1761-1766. 
 
[43] Pauletti, G. M., Gangwar, S., Siahaan, T. J., Aubé, J., & Borchardt, R. T. (1997). 
Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies. 
Advanced drug delivery reviews, 27(2), 235-256. 
 
54 
 
 
[44] Gangwar, S., Pauletti, G. M., Siahaan, T. J., Stella, V. J., & Borchardt, R. T. (1997). 
Synthesis of a novel esterase-sensitive cyclic prodrug of a hexapeptide using an (acyloxy) 
alkoxy promoiety. The Journal of Organic Chemistry, 62(5), 1356-1362. 
 
 
[45] Reddy, M. R., & Erion, M. D. (2001). Free energy calculations in rational drug 
design. Springer Science & Business Media. 
 
[46] Parr, R. G. (1990). On the genesis of a theory. International Journal of Quantum 
Chemistry, 37(4), 327-347. 
 
[47] Chen, T. C. (1955). Expansion of Electronic Wave Functions of Molecules in Terms 
of``United‐Atom''Wave Functions. The Journal of Chemical Physics, 23(11), 2200-2201. 
 
[48] Parr, R. G., & Yang, W. (1989). Density Functional Theory of Atoms and 
MoleculesOxford Univ. Press, New York. 
 
[49] Pople, J. A., Gill, P. M., & Johnson, B. G. (1992). Kohn—Sham density-functional 
theory within a finite basis set. Chemical physics letters, 199(6), 557-560. 
 
[50] Dewar, M. J., & Thiel, W. (1977). Ground states of molecules. 38. The MNDO 
method. Approximations and parameters. Journal of the American Chemical Society, 
99(15), 4899-4907. 
. 
[51] Bingham, R. C., Dewar, M. J., & Lo, D. H. (1975). Ground states of molecules. 
XXV. MINDO/3. Improved version of the MINDO semiempirical SCF-MO method. 
Journal of the American Chemical Society, 97(6), 1285-1293. 
 
[52] Dewar, M. J., Zoebisch, E. G., Healy, E. F., & Stewart, J. J. (1985). Development 
and use of quantum mechanical molecular models. 76. AM1: a new general purpose 
quantum mechanical molecular model. Journal of the American Chemical Society, 
107(13), 3902-3909. 
. 
[53] Dewar, M. J., Jie, C., & Yu, J. (1993). The first of a new series of general purpose 
quantum mechanical molecular models. Tetrahedron, 49(34), 7393. 
 
[54] Di Stefano, A., Sozio, P., & Cerasa, L. S. (2008). Antiparkinson prodrugs. 
Molecules, 13(1), 46-68. 
 
[55] Benes, F. M. (2001). Carlsson and the discovery of dopamine. Trends in 
pharmacological sciences, 22(1), 46-47. 
 
[56] Fahn, S., Keiburtz, K., & Tanner, C. M. (2005). Levodopa and the Progression of 
Parkinson's Disease. The New England Journal of Medicine, 352(13), 1386. 
. 
55 
 
 
[57] Grosset, D., Fernandez, H., Grosset, K., & Okun, M. (2009). Parkinson's Disease: 
Clinican's Desk Reference. CRC Press. 
[58] Lotharius, J., & Brundin, P. (2002). Pathogenesis of Parkinson's disease: dopamine, 
vesicles and α-synuclein. Nature Reviews Neuroscience, 3(12), 932-942. 
[59] Karaman, R. (2011). Computational‐Aided Design for Dopamine Prodrugs Based on 
Novel Chemical Approach. Chemical biology & drug design, 78(5), 853-863. 
[60] Wade, L. A., & Katzman, R. (1975). Synthetic amino acids and the nature of L‐
DOPA transport at the blood‐brain barrier. Journal of neurochemistry, 25(6), 837-842. 
[61] Aminoff, M. (2004). Pharmacologic Management of Parkinsonism & Other 
Movement Katzung Pharmacology Katzung, Basic and Clinical Pharmacology, 483-500. 
[62] Howland, R. D., Mycek, M. J., Harvey, R. A., & Champe, P. C. (2006). Lippincott's 
illustrated reviews: Pharmacology (pp. 159-171). Philadelphia: Lippincott Williams & 
Wilkins. 
[63] Parkinson Study Group. (2004). Levodopa and the progression of Parkinson's 
disease. N Engl J Med, 2004(351), 2498-2508. 
[64] Lang, A. E., & Lozano, A. M. (1998). Parkinson's disease. New England Journal of 
Medicine, 339(15), 1044-1053. 
[65] Standaert, D. G., & Young, A. B. (1996). Treatment of central nervous system 
degenerative disorders. The pharmacological basis of therapeutics. IXth ed. New York: 
McGraw-Hill, 503-519. 
[66] LeWitt, P. A. (2008). Levodopa for the treatment of Parkinson's disease. New 
England Journal of Medicine, 359(23), 2468-2476. 
[67] Nutt, J. G., Woodward, W. R., Beckner, R. M., Stone, C. K., Berggren, K., Carter, J. 
H., ... & Gordin, A. (1994). Effect of peripheral catechol‐O‐methyltransferase inhibition 
on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian 
patients. Neurology, 44(5), 913-913. 
[68] Nutt, J. G. (1999). Effect of COMT inhibition on the pharmacokinetics and 
pharmacodynamics of levodopa in parkinsonian patients. Neurology, 55(11 Suppl 4), 
S33-7. 
[69] Kurlan, R., Rothfield, K. P., Woodward, W. R., Nutt, J. G., Miller, C., Lichter, D., & 
Shoulson, I. (1988). Erratic gastric emptying of levodopa may cause “random” 
fluctuations of parkinsonian mobility. Neurology, 38(3), 419-419. 
[70] Djaldetti, R., Baron, J., Ziv, I., & Melamed, E. (1996). Gastric emptying in 
Parkinson's disease Patients with and without response fluctuations.Neurology, 46(4), 
1051-1054. 
56 
 
 
[71] Palma, P. N., Bonifácio, M. J., Almeida, L., & Soares-da-Silva, P. (2007). 10 
Restoring Dopamine Levels. Protein Misfolding in Neurodegenerative Diseases: 
Mechanisms and Therapeutic Strategies, 415. 
[72] Gordin, A. (1997). COMT inhibitors in the treatment of Parkinson's 
disease.Pharmacology and Toxicology-Supplements, 81(1), S13. 
[73] Olanow, C. W. (2004). The scientific basis for the current treatment of Parkinson's 
disease. Annu. Rev. Med., 55, 41-60. 
[74] Olanow, C. W., Obeso, J. A., & Stocchi, F. (2006). Continuous dopamine-receptor 
treatment of Parkinson's disease: scientific rationale and clinical implications. The Lancet 
Neurology, 5(8), 677-687. 
[75] Di Stefano, A., Sozio, P., Serafina Cerasa, L., & Iannitelli, A. (2011). L-Dopa 
prodrugs: an overview of trends for improving parkinson's disease treatment.Current 
pharmaceutical design, 17(32), 3482-3493. 
[76] Di Stefano, A., Sozio, P., & Cerasa, L. S. (2008). Antiparkinson 
prodrugs.Molecules, 13(1), 46-68. 
[77] Chemuturi, N. V., & Donovan, M. D. (2007). Role of organic cation transporters in 
dopamine uptake across olfactory and nasal respiratory tissues. Molecular 
pharmaceutics, 4(6), 936-942. 
[78] Borgman, R. J., McPhillips, J. J., Stitzel, R. E., & Goodman, I. J. (1973). Synthesis 
and pharmacology of centrally acting dopamine derivatives and analogs in relation to 
Parkinson's disease. Journal of medicinal chemistry,16(6), 630-633. 
[79] Bodor, N., Farag, H. H., & Brewster, M. E. (1981). Site-specific, sustained release of 
drugs to the brain. Science, 214(4527), 1370-1372. 
[80] Prokai, L., Prokai‐Tatrai, K., & Bodor, N. (2000). Targeting drugs to the brain by 
redox chemical delivery systems. Medicinal research reviews, 20(5), 367-416. 
[81] Carelli, V., Liberatore, F., Scipione, L., Impicciatore, M., Barocelli, E., Cardellini, 
M., & Giorgioni, G. (1996). New systems for the specific delivery and sustained release 
of dopamine to the brain. Journal of controlled release,42(3), 209-216. 
[82] Konerth, M., & Childers, J. (2013). Exercise: a possible adjunct therapy to alleviate 
early Parkinson disease. Journal of the American Academy of Physician Assistants, 26(4), 
30-33. 
[83] Giannola, L., De Caro, V., Giandalia, G., Siragusa, M. G., & Lamartina, L. I. L. I. A. 
N. A. (2008). Synthesis and in vitro studies on a potential dopamine prodrug. Die 
Pharmazie-An International Journal of Pharmaceutical Sciences, 63(10), 704-710. 
57 
 
 
[84] More, S. S., & Vince, R. (2008). Design, synthesis and biological evaluation of 
glutathione peptidomimetics as components of anti-Parkinson prodrugs.Journal of 
medicinal chemistry, 51(15), 4581-4588. 
[85] Li, Y., Zhou, Y., Qi, B., Gong, T., Sun, X., Fu, Y., & Zhang, Z. (2014). Brain-
specific delivery of dopamine mediated by N, N-dimethyl amino group for the treatment 
of Parkinson’s disease. Molecular pharmaceutics, 11(9), 3174-3185. 
[86] Fernández, C., Nieto, O., Rivas, E., Montenegro, G., Fontenla, J. A., & Fernández-
Mayoralas, A. (2000). Synthesis and biological studies of glycosyl dopamine derivatives 
as potential antiparkinsonian agents. Carbohydrate research, 327(4), 353-365. 
[87] Fernández, C., Nieto, O., Fontenla, J. A., Rivas, E., de Ceballos, M. L., & 
Fernández-Mayoralas, A. (2003). Synthesis of glycosyl derivatives as dopamine 
prodrugs: interaction with glucose carrier GLUT-1. Organic & biomolecular 
chemistry, 1(5), 767-771. 
[88] Bonina, F., Puglia, C., Rimoli, M. G., Melisi, D., Boatto, G., Nieddu, M., ... & 
Caprariis, P. D. (2003). Glycosyl derivatives of dopamine and L-dopa as anti-Parkinson 
prodrugs: synthesis, pharmacological activity and in vitro stability studies. Journal of 
drug targeting, 11(1), 25-36. 
[89] Ruocco, L. A., Viggiano, D., Viggiano, A., Abignente, E., Rimoli, M. G., Melisi, D. 
... & Carnevale, U. G. (2008). Galactosylated dopamine enters into the brain, blocks the 
mesocorticolimbic system and modulates activity and scanning time in Naples high 
excitability rats. Neuroscience, 152(1), 234-244. 
[90] Karaman, R. (2015). From Conventional Prodrugs to Prodrugs Designed By 
Molecular Orbital Methods. Frontiers in Computational Chemistry, 2, 187-249. 
[91] Karaman, R. (2014). Prodrugs Design Based On Inter-And Intramolecular 
Processes. Nova Science Publishers, Inc. NY, USA, 1-76. 
[92] Ala’Abu-Jaish, S. J., & Karaman, R. (2014) Prodrug Overview. PRODRUGS 
DESIGN,1, 77. 
[93] Fattash, B., & Karaman, R. (2014). Chemical Approaches Used In Prodrugs 
Design. Nova Science Publishers, Inc. NY, USA, 103-138. 
[94] Karaman, R. (2014). Using predrugs to optimize drug candidates. Expert opinion on 
drug discovery, 9(12), 1405-1419. 
58 
 
 
[95] Karaman, R. (2008). Analysis of Menger’s ‘spatiotemporal hypothesis’.Tetrahedron 
Letters, 49(41), 5998-6002. 
[96] Karaman, R. (2009). Cleavage of Menger’s aliphatic amide: a model for peptidase 
enzyme solely explained by proximity orientation in intramolecular proton 
transfer. Journal of Molecular Structure: THEOCHEM, 910(1), 27-33. 
[97] Karaman, R. (2010). A general equation correlating intramolecular rates with 
‘attack’parameters: distance and angle. Tetrahedron Letters, 51(39), 5185-5190. 
[98] Karaman, R. (2009). A new mathematical equation relating activation energy to 
bond angle and distance: a key for understanding the role of acceleration in lactonization 
of the trimethyl lock system. Bioorganic chemistry, 37(1), 11-25. 
[99] Karaman, R. (2009). Reevaluation of Bruice’s proximity orientation. Tetrahedron 
Letters, 50(4), 452-456. 
[100] Karaman, R. (2009). The gem-disubstituent effect—a computational study that 
exposes the relevance of existing theoretical models. Tetrahedron Letters,50(44), 6083-
6087. 
[101] Karaman, R. (2009). Analyzing Kirby’s amine olefin—a model for amino acid 
ammonia lyases. Tetrahedron Letters, 50(52), 7304-7309. 
[102] Karaman, R. (2009). The effective molarity (EM) puzzle in proton transfer 
reactions. Bioorganic chemistry, 37(4), 106-110. 
[103] Karaman, R. (2010). Effects of substitution on the effective molarity (EM) for five 
membered ring-closure reactions–A computational approach. Journal of Molecular 
Structure: Theochem, 939(1), 69-74. 
[104] Karaman, R. (2010). The effective molarity (EM) puzzle in intramolecular ring-
closing reactions. Journal of Molecular Structure: Theochem, 940(1), 70-75. 
[105] Menger, F. M., & Karaman, R. (2010). A singularity model for chemical 
reactivity. Chemistry–A European Journal, 16(5), 1420-1427. 
[106] Karaman, R. (2010). The effective molarity (EM)–a computational 
approach.Bioorganic chemistry, 38(4), 165-172. 
[107] Karaman, R., Blasko, A., Almarsson, O., Arasasingham, R., & Bruice, T. C. 
(1992). Symmetrical and unsymmetrical quadruply aza-bridged, closely interspaced, 
cofacial bis (5, 10, 15, 20-tetraphenylporphyrin) s. 2. Synthesis, characterization, and 
59 
 
 
conformational effects of solvents. Journal of the American Chemical Society, 114(12), 
4889-4898. 
[108] Karaman, R. (2010). Proximity vs. strain in intramolecular ring-closing 
reactions. Molecular Physics, 108(13), 1723-1730. 
[109] Karaman, R. (2011). The role of proximity orientation in intramolecular proton 
transfer reactions. Computational and Theoretical Chemistry, 966(1), 311-321. 
[110] Karaman, R., & Bruice, T. C. (1991). Synthesis and characterization of the first 
water-soluble closely interspaced cofacial porphyrin dimer. The Journal of Organic 
Chemistry, 56(11), 3470-3472. 
[111] Karaman, R. (2011). Analyzing Kemp’s amide cleavage: A model for amidase 
enzymes. Computational and Theoretical Chemistry, 963(2), 427-434. 
[112] Karaman, R., Ghareeb, H., Dajani, K. K., Scrano, L., Hallak, H., Abu-Lafi, S., ... & 
Bufo, S. A. (2013). Design, synthesis and in vitro kinetic study of tranexamic acid 
prodrugs for the treatment of bleeding conditions. Journal of computer-aided molecular 
design, 27(7), 615-635. 
[113] Karaman, R., Dajani, K. K., Qtait, A., & Khamis, M. (2012). Prodrugs of 
Acyclovir–A Computational Approach. Chemical biology & drug design, 79(5), 819-834. 
[114] Karaman, R., Dajani, K., & Hallak, H. (2012). Computer-assisted design for 
atenolol prodrugs for the use in aqueous formulations. Journal of molecular 
modeling, 18(4), 1523-1540. 
[115] Karaman, R. (2013). Prodrugs for masking bitter taste of antibacterial drugs—a 
computational approach. Journal of molecular modeling, 19(6), 2399-2412. 
[116] Karaman, R., Dokmak, G., Bader, M., Hallak, H., Khamis, M., Scrano, L., & Bufo, 
S. A. (2013). Prodrugs of fumarate esters for the treatment of psoriasis and multiple 
sclerosis—a computational approach. Journal of molecular modeling, 19(1), 439-452. 
[117] Karaman, R. (2010). Prodrugs of aza nucleosides based on proton transfer 
reaction. Journal of computer-aided molecular design, 24(12), 961-970. 
[118] Karaman, R., & Hallak, H. (2010). Computer‐Assisted Design of Pro‐drugs for 
Antimalarial Atovaquone. Chemical biology & drug design, 76(4), 350-360. 
[119] Karaman, R. (2013). Antimalarial Atovaquone Prodrugs Based on Enzyme 
Models-Molecular Orbital Calculations Approach. Antimalarial Drug Research and 
Development, Banet, A C. & Brasier, P. Ed, 1-67. 
60 
 
 
[120] Karaman, R., Fattash, B., Mecca, G., & Bader, M. (2014). Computationally 
designed atovaquone prodrugs based on Bruice‘s enzyme model. Current computer-aided 
drug design, 10(1), 15-27. 
[121] Karaman, R., Amly, W., Scrano, L., Mecca, G., & Bufo, S. A. (2013). 
Computationally designed prodrugs of statins based on Kirby’s enzyme model.Journal of 
molecular modeling, 19(9), 3969-3982. 
[122] Karaman, R., Karaman, D., & Zeiadeh, I. (2013). Computationally-designed 
phenylephrine prodrugs–a model for enhancing bioavailability. Molecular 
Physics, 111(21), 3249-3264. 
[123] Almarsson, O., Karaman, R., & Bruice, T. C. (1992). Kinetic importance of 
conformations of nicotinamide adenine dinucleotide in the reactions of dehydrogenase 
enzymes. Journal of the American Chemical Society, 114(22), 8702-8704. 
[124] Jeon, S., Almarsson, O., Karaman, R., Blasko, A., & Bruice, T. C. (1993). 
Symmetrical and unsymmetrical quadruply aza-bridged closely interspaced cofacial bis 
(5, 10, 15, 20-tetraphenylporphyrins). 4. Structure and conformational effects on 
electrochemistry and the catalysis of electrochemical reduction of dioxygen by doubly, 
triply, and quadruply N, N-dimethylene sulfonamide bridged dimer bis (cobalt 
tetraphenylporphyrins). Inorganic Chemistry, 32(11), 2562-2569. 
[125] Horani, W., Thawabteh, A., Scrano, L., Bufo, S. A., Mecca, G., & Karaman, R. 
(2015). Anti-cancer Prodrugs-Three Decades of Design. World Journal of Pharmacy & 
Pharmaceutical Sciences World Journal of Pharmacy & Pharmaceutical Sciences, 4(7), 
1751-1779. 
[126] Karaman, R. (2015). Design of prodrugs to replace commonly used drugs having 
bitter sensation. World Journal of Pharmaceutical Research, 4(2), 49-58. 
[127] Hejaz, H., Karaman, R., & Khamis, M. (2012). Computer-assisted design for 
paracetamol masking bitter taste prodrugs. Journal of molecular modeling,18(1), 103-
114. 
[128] Abu-Jaish, A., Mecca, G., Jumaa, S., Thawabteh, A., & Karaman, R. (2015). 
Mefenamic acid Prodrugs and Codrugs-Two Decades of Development. World Journal of 
Pharmaceutical Research, 4(6), 2408-2429. 
[129] Karaman, R. (2015). Computationally Designed Prodrugs Based on Enzyme 
Models‖ Aperito Journal of Drug Designing and Pharmacol 2015, 2: 111. 
61 
 
 
[130] Karaman, R., Jumaa, S., Awwadallah, H., Salah, S., Khawaja, Y., & Karaman, D. 
(2016). Intramolecular Processes and Their Applications in Prodrugs Approaches-
Experimental and Computational Studies. Current Organic Chemistry, 20(3), 289-315. 
[131] Karaman, R.(2011). Analyzing the efficiency in intramolecular amide hydrolysis of 
Kirby’s N-alkylmaleamic acids - a computational approach. Comput. Theor. Chem., 
974,133–142. 
[132] Kirby, A. J., & Lancaster, P. W. (1972). Structure and efficiency in intramolecular 
and enzymic catalysis. Catalysis of amide hydrolysis by the carboxy-group of substituted 
maleamic acids. J. Chem. Soc., Perkin Trans. 2, (9), 1206-1214. 
[133] Oda, A. and O. Takahashi. (2009). Validation of ArgusLab efficiencies for binding 
free energy calculations. Chem-Bio Informatics Journal, 9, 52-61. 
[134] Frisch, M. J., Trucks, G. W., Schlegel, H. B., Scuseria, G. E., Robb, M. A., 
Cheeseman, J. R., ... & Nakatsuji, H. (2010). Gaussian 09: EM64L-G09RevB. 01, 
Gaussian. Inc., Wallingford. 
.[135] Schaftenaar, G., & Noordik, J. H. (2000). Molden: a pre-and post-processing 
program for molecular and electronic structures. Journal of computer-aided molecular 
design, 14(2), 123-134. 
[136] Frisch, M. J., Trucks, G. W., Schlegel, H. B., Scuseria, G. E., Robb, M. A., 
Cheeseman, J. R., ... & Nakatsuji, H. (2009). RA Gaussian 09, Gaussian. Inc., 
Wallingford, CT. 
 
[137] Casewit, C. J., Colwell, K. S., & Rappe, A. K. (1992). Application of a universal 
force field to main group compounds. Journal of the American Chemical Society, 
114(25), 10046-10053. 
 
[138] Murrell, J. N., & Laidler, K. J. (1968). Symmetries of activated complexes. 
Transactions of the Faraday Society, 64, 371-377. 
 
[139] Müller, K. (1980). Reaction paths on multidimensional energy hypersurfaces. 
Angewandte Chemie International Edition in English, 19(1), 1-13. 
 
[140] Cances, E., Mennucci, B., & Tomasi, J. (1997). A new integral equation formalism 
for the polarizable continuum model: Theoretical background and applications to 
isotropic and anisotropic dielectrics. The Journal of chemical physics, 107(8), 3032-3041. 
 
[141] Mennucci, B., & Tomasi, J. (1997). Continuum solvation models: a new approach 
to the problem of solute’s charge distribution and cavity boundaries. The Journal of 
chemical physics, 106(12), 5151-5158. 
62 
 
 
 
[142] Mennucci, B., Cances, E., & Tomasi, J. (1997). Evaluation of solvent effects in 
isotropic and anisotropic dielectrics and in ionic solutions with a unified integral equation 
method: theoretical bases, computational implementation, and numerical applications. 
The Journal of Physical Chemistry B, 101(49), 10506-10517. 
 
[143] Tomasi, J., Mennucci, B., & Cances, E. (1999). The IEF version of the PCM 
solvation method: an overview of a new method addressed to study molecular solutes at 
the QM ab initio level. Journal of Molecular Structure: THEOCHEM, 464(1), 211-226. 
 
[144] Kirby, A. J., & Williams, N. H. (1994). Efficient intramolecular general acid 
catalysis of enol ether hydrolysis. Hydrogen-bonding stabilisation of the transition state 
for proton transfer to carbon. J. Chem. Soc., Perkin Trans. 2, (4), 643-648. 
 
[145] Burkert, U., & Allinger, N. L. (1982). Molecular mechanics (Vol. 177, p. 339). 
Washington, DC: American Chemical Society. 
 
[146]  Kirby, A. J., & Lancaster, P. W. (1972). Structure and efficiency in intramolecular 
and enzymic catalysis. Catalysis of amide hydrolysis by the carboxy-group of substituted 
maleamic acids. Journal of the Chemical Society, Perkin Transactions 2, (9), 1206-1214. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Material 
 
 
 
 
 
 
 
64 
 
 
 
Supplementary Material 
Xyz Cartesian coordinates for the DFT optimized GM, TS and P in processes Dopamine 
ProD 1- ProD 5. 
 
Dopamine ProD 1GM 
 C    -4.019845    -0.164614    -0.476160  M H 
 C    -3.408892     1.013659    -0.008612  H   
 C    -2.252503     0.954040     0.757795  M H 
 C    -1.669030    -0.283294     1.081006  H   
 C    -2.283033    -1.447952     0.609111  H   
 C    -3.448392    -1.392342    -0.161736  H   
 C    -0.387223    -0.339305     1.886379  H   
 C     0.872835    -0.013776     1.061547  H   
 N     1.050167    -0.958617    -0.030427  H   
 C     2.214519    -1.416258    -0.559007  L H 
 O     2.270117    -2.065945    -1.597720  H   
 O    -4.050066     2.177811    -0.366748  H   
 O    -5.156891    -0.103582    -1.223539  H   
 C     3.498757    -1.264970     0.219664  H   
 C     4.317937    -0.205441     0.281923  M H 
 C     3.999309     1.113095    -0.305445  L H 
 O     2.943190     1.447701    -0.807465  H   
 O     5.059691     1.955022    -0.218507  H   
 H    -1.799982     1.878773     1.112912  H   
 H    -1.853060    -2.415547     0.851618  H   
 H    -3.926636    -2.295750    -0.525041  M H 
 H    -5.382782     0.832140    -1.335791  H   
 H    -0.273127    -1.334904     2.328378  M H 
 H    -0.434175     0.376808     2.716104  H   
 H     1.754727    -0.064356     1.704956  H   
 H     0.816944     1.009507     0.669699  H   
 H     0.251228    -1.107383    -0.637289  H   
 H     3.847079    -2.205174     0.642803  H   
 H     5.292025    -0.295177     0.752230  H   
 H     4.776545     2.786820    -0.633812  L H 
 H    -3.554936     2.939462    -0.040739  H 
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Dopamine ProD 2GM 
 C     0.000000     0.000000     0.000000  M H 
 C     0.000000     0.000000     1.397076  H   
 C     1.221221     0.000000     2.107387  M H 
 C     2.432548     0.000636     1.406504  H   
 C     2.427151     0.004447     0.006803  H   
 C     1.212736     0.002446    -0.687277  H   
 O     1.285078     0.002672     3.478320  H   
 O    -1.148052    -0.002072     2.159579  H   
 C     3.720618     0.006522    -0.730794  H   
 C     4.365052     1.399177    -0.769472  L H 
 N     3.690200     2.326865    -1.636223  H   
 C     3.774140     3.696183    -1.491526  H   
 O     3.350545     4.439520    -2.397126  H   
 C     4.294346     4.258660    -0.203421  H   
 C     3.265609     4.417224     0.853801  M H 
 C     5.567456     4.663536    -0.033553  L H 
 C     6.030485     5.298190     1.228212  H H 
 C     6.606524     4.544350    -1.072385  H   
 O     7.521173     5.328611    -1.335016  H   
 O     6.570693     3.397392    -1.811352  H   
 H     3.377036    -0.004007     1.968160  M H 
 H     1.210621     0.006894    -1.786687  H   
 H    -0.950742    -0.000465    -0.550417  M   
 H     0.379523    -0.021092     3.820346  H   
 H    -1.902842    -0.008418     1.556408  H   
 H     4.445910    -0.678745    -0.216783  H   
 H     3.573049    -0.382332    -1.771864  H   
 H     5.436651     1.284197    -1.109705  H   
 H     4.377069     1.820484     0.275929  H   
 H     3.376904     1.982388    -2.514247  L H 
 H     7.272632     3.424222    -2.480771  H   
 H     3.658505     4.055029     1.836233  H   
 H     2.337701     3.847347     0.606877  M H 
 H     2.998974     5.499416     0.959754  L H 
 H     7.019120     5.799418     1.085420  L H 
 H     6.130499     4.524880     2.029917  H   
 H     5.290495     6.063729     1.570262  M H 
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Dopamine ProD 3GM 
 
 C     0.000000     0.000000     0.000000 
 C     0.000000     0.000000     1.400794 
 C     1.229891     0.000000     2.096180 
 C     2.438120    -0.000567     1.397145 
 C     2.430961     0.001682    -0.003300 
 C     1.211175     0.000573    -0.688406 
 O     1.150192     0.001206     3.472566 
 O    -1.215119    -0.000864     2.036259 
 C     3.719860    -0.011358    -0.746850 
 C     4.464163     1.329624    -0.648531 
 N     3.810507     2.446457    -1.271776 
 C     4.009958     2.826605    -2.588719 
 C     5.213639     2.313348    -3.359517 
 C     6.499800     2.961966    -2.878069 
 C     7.598488     1.954088    -2.744751 
 O     8.820530     2.406573    -3.131097 
 O     3.216295     3.630484    -3.114193 
 O     7.544782     0.797452    -2.317482 
 H     3.390499    -0.005793     1.945114 
 H     1.202541    -0.002249    -1.788339 
 H    -0.959096    -0.001071    -0.536438 
 H     2.050753    -0.029058     3.820872 
 H    -1.055013    -0.008321     2.991297 
 H     3.545486    -0.271989    -1.822978 
 H     4.391753    -0.800159    -0.315731 
 H     5.492219     1.196176    -1.092961 
 H     4.588079     1.582550     0.443858 
 H     2.944608     2.724417    -0.863753 
 H     5.047612     2.560924    -4.440994 
 H     5.268838     1.195943    -3.271488 
 H     6.816914     3.772334    -3.585577 
 H     6.367610     3.432563    -1.866511 
 H     9.485553     1.711953    -3.001399 
 
 
Dopamine ProD 4GM 
 
 C     0.000000     0.000000     0.000000  M H 
 C     0.000000     0.000000     1.555752  H H 
 C     1.460311     0.000000     2.096633  M H 
 C     2.173514     1.314472     1.675909  H H 
 C     1.716534     1.851894     0.295267  H H 
 C     1.244575     0.692312    -0.593812  H H 
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 C    -0.943652    -1.062917     2.141172  H   
 O    -1.953442    -0.711529     2.744691  H   
 C     1.479342    -0.228301     3.597092  H   
 O     1.786127    -1.270841     4.138666  L H 
 N    -0.700152    -2.398481     1.934056  H   
 C     0.525857    -3.086651     1.534586  H   
 C     0.212521    -4.547452     1.168644  H   
 C     1.447168    -5.304933     0.730285  H   
 C     2.279469    -5.924495     1.667821  M H 
 C     3.441064    -6.588264     1.262349  L H 
 C     3.777851    -6.635868    -0.084912  H   
 C     2.951893    -6.019162    -1.040392  H   
 C     1.798278    -5.360652    -0.626347  H   
 O     4.892386    -7.263179    -0.597402  H   
 O     3.273596    -6.066750    -2.364038  M H 
 O     1.073280     0.854826     4.299288  H   
 H     4.081962    -7.071457     1.996698  M   
 H     2.023893    -5.895056     2.723010  H   
 H     1.173327    -4.897820    -1.384479  H   
 H     5.397993    -7.667741     0.118189  H   
 H     4.096983    -6.571515    -2.444877  H   
 H    -0.543325    -4.558784     0.375295  H   
 H    -0.233803    -5.041749     2.041457  H   
 H     0.958155    -2.592558     0.660063  L H 
 H     1.275325    -3.056484     2.335459  H   
 H    -1.380292    -2.964143     2.428883  H   
 H    -0.457234     0.929442     1.904323  M H 
 H     2.001423    -0.850802     1.679073  L H 
 H     3.253800     1.123322     1.652970  L H 
 H     2.005981     2.081525     2.437077  H   
 H     0.851629     2.511393     0.456275  M H 
 H     2.066605    -0.028896    -0.703182  L H 
 H     1.019821     1.050890    -1.604871  L H 
 H    -0.908430     0.515693    -0.330122  H   
 H    -0.076443    -1.021309    -0.385448  H   
 H     1.056357     0.582764     5.232393  H   
 H     2.593915     2.317666    -0.151029  H   
 
 
Dopamine ProD 5GM 
 
 C     0.000000     0.000000     0.000000  M H 
 C     0.000000     0.000000     1.527022  H   
 C     1.428386     0.000000     2.067591  M H 
 C     2.137866     1.301820     1.691722  H H 
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 C     1.702631     1.819451     0.323773  H   
 C     1.233006     0.679270    -0.567784  H H 
 C    -0.899816    -1.113337     2.053652  H   
 O    -2.012106    -0.813512     2.536445  H   
 C     1.452870    -0.199772     3.559499  H   
 O     1.852235    -1.188158     4.181077  L H 
 C     2.830486     2.586707    -0.336122  H   
 N    -0.578093    -2.450217     1.977120  H H 
 C     0.692954    -3.002202     1.598562  H   
 C     0.633989    -4.513966     1.327004  H   
 C     1.995723    -5.015466     0.988397  M H 
 C     2.910428    -5.298823     2.009557  L H 
 C     4.185864    -5.772036     1.709935  H   
 C     4.553416    -5.962914     0.374953  H   
 C     3.637542    -5.679414    -0.661828  H   
 C     2.356972    -5.206475    -0.348928  H   
 O     5.792758    -6.422854    -0.014725  M H 
 O     3.942889    -5.840830    -1.989930  H   
 O     0.989880     0.840413     4.301158  M H 
 H     4.900270    -5.993262     2.514725  H   
 H     2.620964    -5.143741     3.059236  H   
 H     1.652000    -4.993190    -1.164435  H   
 H     6.302546    -6.609824     0.784396  H   
 H     4.843152    -6.192344    -2.049784  H   
 H    -0.076681    -4.723690     0.485993  H   
 H     0.251936    -5.050502     2.235131  L H 
 H     1.057148    -2.487945     0.664181  H   
 H     1.447169    -2.819769     2.421553  H   
 H    -1.235257    -3.082057     2.377721  M H 
 H    -0.483235     0.957859     1.884758  L H 
 H     2.001562    -0.858989     1.617365  L H 
 H     3.242808     1.116404     1.698118  H   
 H     1.923217     2.086712     2.462337  M H 
 H     0.834622     2.521237     0.473121  L H 
 H     2.061374    -0.067402    -0.677990  L H 
 H     1.002092     1.073514    -1.590263  H   
 H    -0.922684     0.533005    -0.348385  H   
 H    -0.056480    -1.045352    -0.397629  H   
 H     1.018154     0.607750     5.242997  H   
 H     2.473614     3.061122    -1.280593  H   
 H     3.679163     1.905601    -0.582074  H   
 H     3.204047     3.387087     0.345183  H   
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Dopamine ProD 1TS 
 
 O     0.000000     0.000000     0.000000 
 C     0.000000     0.000000     1.492114 
 C     1.488364     0.000000     1.807878 
 C     2.210069    -0.033626     0.689812 
 C     1.279687    -0.089935    -0.472579 
 N    -0.912209    -1.420282     2.229431 
 C    -0.640648    -2.764083     1.707733 
 C    -1.514743    -3.181540     0.499616 
 C    -0.968843    -4.399045    -0.212215 
 C    -1.329033    -5.698424     0.156161 
 C    -0.775689    -6.810740    -0.484651 
 C     0.151457    -6.638963    -1.507553 
 C     0.519015    -5.335377    -1.884961 
 C    -0.032258    -4.232214    -1.246620 
 O     0.691623    -7.720220    -2.140035 
 O     1.436186    -5.262487    -2.909663 
 O    -0.656418     1.150645     1.922401 
 O     1.542649    -0.210254    -1.645106 
 H    -1.058052    -7.820583    -0.205666 
 H    -2.056983    -5.850243     0.948643 
 H     0.262754    -3.231091    -1.558075 
 H     1.295701    -7.384316    -2.819381 
 H     1.613819    -4.336920    -3.120667 
 H    -1.566363    -2.339075    -0.195008 
 H    -2.536264    -3.374516     0.851188 
 H     0.415655    -2.811352     1.428027 
 H    -0.771629    -3.487107     2.520949 
 H    -1.903237    -1.198795     2.259262 
 H     1.826779     0.027120     2.836300 
 H     3.285069    -0.039721     0.568125 
 H    -0.322526     1.891320     1.397583 
 
 
Dopamine ProD 2TS 
 
 O     0.000000     0.000000     0.000000  M H 
 C     0.000000     0.000000     1.468718  H   
 C     1.485280     0.000000     1.826865  M H 
 C     2.220753     0.006016     0.705476  H   
 C     1.293231    -0.012538    -0.460088  H   
 N    -0.942122    -1.405339     2.196998  H   
 C    -0.579860    -2.755266     1.762781  H   
 C    -1.371598    -3.810308     2.555894  H   
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 C    -2.870677    -3.729535     2.352963  H   
 C    -3.490619    -4.368347     1.273199  L H 
 C    -4.867818    -4.269205     1.066340  H   
 C    -5.655654    -3.524716     1.939717  H   
 C    -5.044483    -2.879296     3.027573  H   
 C    -3.672450    -2.980936     3.230856  H   
 O    -7.001058    -3.429500     1.743460  M H 
 O    -5.902424    -2.171899     3.840206  L H 
 O    -0.662386     1.160870     1.895588  H   
 C     1.890392     0.033677     3.260867  H H 
 C     3.698937     0.035853     0.490607  H   
 O     1.569740    -0.025422    -1.634670  H   
 H    -5.349587    -4.767708     0.231769  M H 
 H    -2.892309    -4.957159     0.583347  H   
 H    -3.218163    -2.478465     4.082952  M H 
 H    -7.359079    -2.870703     2.449627  H   
 H    -5.404097    -1.741334     4.545815  H   
 H    -1.131616    -3.697264     3.619017  H   
 H    -1.012648    -4.798918     2.247522  H   
 H    -0.744840    -2.901858     0.684801  H   
 H     0.490300    -2.901539     1.947695  H   
 H    -1.934516    -1.231837     2.055553  L H 
 H    -0.413233     1.866432     1.282588  H   
 H     3.987307     0.923698    -0.082363  H   
 H     4.016879    -0.830182    -0.099462  M H 
 H     4.248953     0.036361     1.434167  M H 
 H     1.515613    -0.852964     3.784150  M H 
 H     1.433998     0.899015     3.754465  H   
 H     2.974237     0.087031     3.382695  M H 
 
 
Dopamine ProD 3TS 
 
 O     0.000000     0.000000     0.000000  M H 
 C     0.000000     0.000000     1.449036  H   
 C     1.484298     0.000000     1.845365  M H 
 C     2.141395     0.725541     0.670000  H   
 C     1.191485     0.465900    -0.491910  H   
 N    -0.869375     1.554767     1.917920  H   
 C    -1.290172     1.687327     3.314160  H   
 C    -1.972987     3.048157     3.542392  H   
 C    -3.249054     3.224420     2.744929  H   
 C    -4.473871     2.748778     3.226685  L H 
 C    -5.645473     2.874763     2.477387  H   
 C    -5.614151     3.480392     1.224366  H   
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 C    -4.390413     3.963315     0.730245  H   
 C    -3.225857     3.837655     1.480530  H   
 O    -6.755716     3.606461     0.491696  M H 
 O    -4.458978     4.551914    -0.511500  L H 
 O    -0.589783    -1.184241     1.896931  H   
 O     1.379835     0.625096    -1.667999  H   
 H    -6.596539     2.511734     2.852767  H   
 H    -4.518582     2.278479     4.205289  H   
 H    -2.289406     4.226633     1.084732  M H 
 H    -6.521466     4.045872    -0.339834  H   
 H    -3.576884     4.816588    -0.800901  M   
 H    -1.259690     3.840590     3.290532  H   
 H    -2.192797     3.139196     4.612147  H   
 H    -1.966149     0.879129     3.634157  H   
 H    -0.401692     1.623796     3.952871  H   
 H    -1.661888     1.689498     1.293089  H   
 H     1.647263     0.480596     2.810977  H   
 H     1.819833    -1.037737     1.910639  L H 
 H     3.146329     0.382421     0.417883  H   
 H     2.183983     1.807864     0.830245  H   
 H    -1.511504    -1.191835     1.598609  M H 
 
 
Dopamine ProD 4TS 
 
 O     0.000000     0.000000     0.000000  M H 
 C     0.000000     0.000000     1.441586  H   
 C     1.489776     0.000000     1.857147  M H 
 C     2.136664    -0.767552     0.677266  H   
 C     1.181162    -0.508143    -0.480376  H   
 C     3.586881    -0.346216     0.356684  H   
 C     4.310346     0.051153     1.649327  H H 
 C     3.635318     1.271932     2.323154  H   
 C     2.128487     1.386420     1.991583  H H 
 N    -0.984269     1.467962     1.916142  L H 
 C    -1.430759     1.525317     3.309273  H   
 C    -2.193805     2.834986     3.576203  H   
 C    -3.465767     2.968791     2.764091  H   
 C    -4.669869     2.411157     3.208809  H   
 C    -5.835526     2.500053     2.445066  M H 
 C    -5.818918     3.150449     1.214408  L H 
 C    -4.616187     3.715495     0.757672  H   
 C    -3.457517     3.626255     1.522034  H   
 O    -6.955114     3.241018     0.467671  H   
 O    -4.697895     4.343109    -0.464485  H   
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 O    -0.519695    -1.241264     1.882866  M H 
 O     1.367337    -0.673916    -1.656824  H   
 H    -6.770785     2.073207     2.791978  M   
 H    -4.703027     1.904730     4.169664  H   
 H    -2.537202     4.077023     1.155042  H   
 H    -6.732736     3.722146    -0.343731  H   
 H    -3.828120     4.670851    -0.725039  H   
 H    -1.524260     3.676308     3.366207  H   
 H    -2.435037     2.872393     4.644636  H   
 H    -2.060362     0.667006     3.589103  L H 
 H    -0.546696     1.488944     3.956317  H   
 H    -1.775373     1.560507     1.282666  H   
 H     1.587563    -0.554072     2.795006  M   
 H     2.098594    -1.844699     0.879310  M H 
 H     1.616024     1.979851     2.753203  M H 
 H     1.987896     1.929579     1.049601  H   
 H     4.133921     2.195538     2.007932  M H 
 H     3.771225     1.207221     3.409080  M H 
 H     4.300660    -0.805820     2.335218  M H 
 H     5.364851     0.265592     1.445904  H   
 H     3.584516     0.496938    -0.343587  H   
 H     4.104826    -1.162580    -0.154333  H   
 H    -1.389624    -1.353504     1.470665  H   
 
 
Dopamine ProD 5TS 
 
 O     0.000000     0.000000     0.000000  M H 
 C     0.000000     0.000000     1.413281  H   
 C     1.452091     0.000000     1.892137  M H 
 C     2.179566    -0.639275     0.677165  H   
 C     1.237543    -0.377543    -0.488611  H   
 C     3.603742    -0.102111     0.430646  H   
 C     4.292299     0.167885     1.774301  H H 
 C     3.543210     1.254718     2.588045  H   
 C     2.050589     1.376113     2.206106  H H 
 N    -0.861874     1.571693     1.781863  L H 
 C    -1.575563     1.459885     3.053494  H   
 C    -2.508091     2.674274     3.255847  H   
 C    -3.649425     2.735421     2.262645  H   
 C    -4.858483     2.075133     2.508740  H   
 C    -5.900342     2.097619     1.578706  M H 
 C    -5.751293     2.783961     0.377103  L H 
 C    -4.542470     3.451984     0.119131  H   
 C    -3.508280     3.428520     1.048455  H   
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 O    -6.766319     2.810618    -0.532989  H   
 O    -4.488789     4.108113    -1.090466  H   
 O    -0.678514    -1.082605     1.913966  M H 
 O     1.451899    -0.454880    -1.666574  H   
 H    -6.840167     1.590947     1.772175  M   
 H    -4.994545     1.539299     3.444333  H   
 H    -2.581012     3.956328     0.833035  H   
 H    -6.462014     3.331817    -1.291247  H   
 H    -3.618035     4.507929    -1.207370  H   
 H    -1.904690     3.586667     3.193200  H   
 H    -2.911446     2.623745     4.274068  H   
 H    -2.168593     0.536825     3.157621  L H 
 H    -0.835868     1.449553     3.864149  H   
 H    -1.552745     1.550307     1.026998  H   
 H     1.513646    -0.642569     2.775221  M   
 H     2.218104    -1.728897     0.804907  M H 
 H     1.486517     1.861876     3.005161  M H 
 H     1.929459     2.021220     1.329569  H   
 H     4.019788     2.229704     2.436990  M H 
 H     3.634285     1.033537     3.657920  M H 
 H     5.334518     0.462802     1.613998  M H 
 H     3.557423     0.820731    -0.158580  H   
 H     4.168112    -0.819951    -0.171042  H   
 H    -1.519595    -1.158612     1.437892  H   
 C     4.799483    -0.847647     2.676497  H   
 H     5.236782    -0.369820     3.551924  H   
 H     4.016028    -1.135999     3.375763  H   
 H     5.350787    -1.595399     2.108297  H   
 
 
Dopamine ProD 1P 
 
 O     2.535086    -0.767970    -0.945705 
 C     3.683824    -0.003575    -0.694514 
 C     4.185361    -0.397517     0.651714 
 C     3.394618    -1.361746     1.129660 
 C     2.307518    -1.594448     0.142123 
 N     2.118088     2.035683     0.821779 
 C     0.690960     1.714219     0.985049 
 C    -0.011325     1.622344    -0.379313 
 C    -1.408488     1.050704    -0.275831 
 C    -2.535618     1.869253    -0.162198 
 C    -3.815324     1.322830    -0.026055 
 C    -3.986549    -0.057450     0.000438 
 C    -2.857774    -0.887334    -0.114447 
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 C    -1.588522    -0.342094    -0.252675 
 O    -5.232667    -0.598460     0.130960 
 O    -3.120456    -2.239237    -0.084454 
 O     4.146316     0.743673    -1.505630 
 O     1.360488    -2.334280     0.205071 
 H    -4.692779     1.955781     0.056945 
 H    -2.419587     2.949594    -0.184830 
 H    -0.730881    -1.005751    -0.346619 
 H    -5.129666    -1.562037     0.118074 
 H    -2.291169    -2.729006    -0.158400 
 H     0.602402     1.001238    -1.039769 
 H    -0.049233     2.623771    -0.827773 
 H     0.618534     0.743360     1.491556 
 H     0.146911     2.434646     1.617825 
 H     2.221804     2.852152     0.221915 
 H     5.066972     0.052538     1.087129 
 H     3.448185    -1.901093     2.065418 
 H     2.519657     2.294120     1.720414 
 
 
Dopamine ProD 2P 
 
 O     0.000000     0.000000     0.000000  M H 
 C     0.000000     0.000000     1.468718  H H 
 C     1.485280     0.000000     1.826865  M H 
 C     2.220753     0.006016     0.705476  H   
 C     1.293231    -0.012538    -0.460088  H   
 N    -1.534401    -2.288826     2.654843  H   
 C    -1.172138    -3.638752     2.220625  H   
 C    -1.963877    -4.693794     3.013738  H   
 C    -3.462956    -4.613022     2.810807  H   
 C    -4.082897    -5.251834     1.731043  L H 
 C    -5.460097    -5.152691     1.524184  H   
 C    -6.247933    -4.408202     2.397561  H   
 C    -5.636761    -3.762783     3.485417  H   
 C    -4.264729    -3.864423     3.688700  H   
 O    -7.593337    -4.312986     2.201304  M H 
 O    -6.494703    -3.055386     4.298050  L H 
 C     1.890392     0.033677     3.260867  H H 
 C     3.698937     0.035853     0.490607  H   
 O     1.569740    -0.025422    -1.634670  H   
 H    -5.941865    -5.651194     0.689613  H   
 H    -3.484588    -5.840646     1.041191  M   
 H    -3.810442    -3.361952     4.540796  H   
 H    -7.951358    -3.754190     2.907471  M   
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 H    -5.996375    -2.624821     5.003659  H   
 H    -1.723895    -4.580751     4.076861  H   
 H    -1.604926    -5.682405     2.705367  H   
 H    -1.337119    -3.785345     1.142645  H   
 H    -0.101979    -3.785025     2.405539  H   
 H    -2.526795    -2.115323     2.513397  H   
 H     3.987307     0.923698    -0.082363  L H 
 H     4.016879    -0.830182    -0.099462  H   
 H     4.248953     0.036361     1.434167  H   
 H     1.515613    -0.852964     3.784150  M H 
 H     1.433998     0.899015     3.754465  M H 
 H     2.974237     0.087031     3.382695  L H 
 H    -1.323862    -2.183296     3.634945  H   
 O    -1.319871     0.012797     1.935385  M H 
 
 
Dopamine ProD 3P 
 
 O     0.000000     0.000000     0.000000  M H 
 C     0.000000     0.000000     1.409171  H   
 C     1.443559     0.000000     1.867178  M H 
 C     2.132814     0.728913     0.710010  H   
 C     1.208881     0.481756    -0.474241  H   
 N    -1.087614     2.723317     2.042134  H   
 C    -1.650768     2.734753     3.391077  H   
 C    -2.388960     4.064357     3.663316  H   
 C    -3.620944     4.260729     2.805373  H   
 C    -4.871725     3.786049     3.215540  L H 
 C    -6.003385     3.931761     2.409733  H   
 C    -5.904454     4.557676     1.170627  H   
 C    -4.653914     5.039519     0.748186  H   
 C    -3.530108     4.893690     1.553978  H   
 O    -7.006682     4.704483     0.381539  M H 
 O    -4.654049     5.648129    -0.487069  L H 
 O    -0.754589    -1.003987     1.925680  H   
 O     1.404728     0.649341    -1.644402  H   
 H    -6.974629     3.569608     2.730563  H   
 H    -4.968760     3.300180     4.182729  H   
 H    -2.570676     5.277225     1.211745  M H 
 H    -6.726136     5.160074    -0.426520  H   
 H    -3.758178     5.925434    -0.715759  M   
 H    -1.683622     4.887600     3.504179  H   
 H    -2.673369     4.082919     4.721990  H   
 H    -2.340349     1.898753     3.594883  H   
 H    -0.826210     2.644954     4.110245  H   
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 H    -1.863588     2.752228     1.374956  H   
 H     1.560295     0.483667     2.836994  H   
 H     1.781552    -1.038909     1.947473  L H 
 H     3.142916     0.387068     0.478379  H   
 H     2.161390     1.808917     0.882603  H   
 H    -0.492985     3.527945     1.919440  L H 
 
 
Dopamine ProD 4P 
 
 O     0.000000     0.000000     0.000000 
 C     0.000000     0.000000     1.441586 
 C     1.489776     0.000000     1.857147 
 C     2.136664    -0.767552     0.677266 
 C     1.181162    -0.508143    -0.480376 
 C     3.586881    -0.346216     0.356684 
 C     4.310346     0.051153     1.649327 
 C     3.635318     1.271932     2.323154 
 C     2.128487     1.386420     1.991583 
 N    -1.613555     2.406495     2.219546 
 C    -2.060045     2.463850     3.612677 
 C    -2.823092     3.773519     3.879607 
 C    -4.095053     3.907324     3.067496 
 C    -5.299156     3.349690     3.512213 
 C    -6.464812     3.438586     2.748470 
 C    -6.448205     4.088982     1.517812 
 C    -5.245474     4.654028     1.061077 
 C    -4.086804     4.564788     1.825438 
 O    -7.584400     4.179551     0.771075 
 O    -5.327182     5.281642    -0.161081 
 O    -0.519695    -1.241264     1.882866 
 O     1.367337    -0.673916    -1.656824 
 H    -7.400071     3.011740     3.095383 
 H    -5.332314     2.843263     4.473068 
 H    -3.166488     5.015556     1.458446 
 H    -7.362022     4.660679    -0.040327 
 H    -4.457407     5.609384    -0.421635 
 H    -2.153547     4.614841     3.669611 
 H    -3.064324     3.810926     4.948041 
 H    -2.689648     1.605539     3.892507 
 H    -1.175983     2.427477     4.259721 
 H    -2.404659     2.499040     1.586071 
 H     1.587563    -0.554072     2.795006 
 H     2.098594    -1.844699     0.879310 
 H     1.616024     1.979851     2.753203 
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 H     1.987896     1.929579     1.049601 
 H     4.133921     2.195538     2.007932 
 H     3.771225     1.207221     3.409080 
 H     4.300660    -0.805820     2.335218 
 H     5.364851     0.265592     1.445904 
 H     3.584516     0.496938    -0.343587 
 H     4.104826    -1.162580    -0.154333 
 H    -0.964546     3.157407     2.043529 
 
 
Dopamine ProD 5P 
 
 O    -1.408551     1.245472     1.447692  M H 
 C    -1.908610    -0.028904     1.704266  H   
 C    -3.197463    -0.245142     0.917531  M H 
 C    -3.500236     1.135448     0.299326  H H 
 C    -2.244749     1.949078     0.559000  H   
 C    -3.874827     1.079176    -1.194204  H   
 C    -4.887732    -0.049777    -1.470570  H H 
 C    -4.295048    -1.435389    -1.056940  H H 
 C    -3.046369    -1.351339    -0.155893  H H 
 N     0.405296    -1.413191    -0.847466  L H 
 C     0.946563    -2.198347     0.267537  H   
 C     2.452960    -2.545936     0.185008  H   
 C     3.354466    -1.330927     0.164343  H   
 C     3.688625    -0.660839     1.347489  H   
 C     4.487045     0.483643     1.332399  M H 
 C     4.970763     0.985703     0.127111  L H 
 C     4.642263     0.323745    -1.066497  H   
 C     3.843474    -0.815437    -1.046904  H   
 O     5.757968     2.099062     0.110437  H   
 O     5.168208     0.887668    -2.209218  H   
 O    -1.332708    -0.783028     2.438625  M H 
 O    -1.940655     3.023086     0.123499  H   
 H     4.748777     0.999821     2.250101  M   
 H     3.321547    -1.038350     2.297768  H   
 H     3.611948    -1.319555    -1.984205  H   
 H     5.984560     2.280900    -0.813905  H   
 H     4.925878     0.355686    -2.976964  H   
 H     2.630209    -3.156010    -0.711080  H   
 H     2.704985    -3.178178     1.045900  H   
 H     0.750139    -1.645634     1.191436  L H 
 H     0.371733    -3.129695     0.334431  H   
 H     0.940355    -0.550851    -0.937895  H   
 H    -3.969714    -0.549153     1.632541  L H 
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 H    -4.304567     1.632779     0.854960  L H 
 H    -2.866711    -2.308216     0.343174  M H 
 H    -2.144866    -1.159551    -0.746269  H   
 H    -4.030553    -2.016898    -1.946760  L H 
 H    -5.073194    -2.011789    -0.541514  L H 
 H    -5.067610    -0.060303    -2.552399  M H 
 H    -2.970841     0.912460    -1.790606  H   
 H    -4.274416     2.048447    -1.506769  H   
 C    -6.238764     0.218039    -0.786702  H   
 H    -6.974306    -0.541727    -1.070330  H   
 H    -6.156312     0.195921     0.306561  H   
 H    -6.643548     1.196051    -1.070318  H   
 H     0.541177    -1.918676    -1.721680  H   
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 النهج الحسابي –الدوبامين   من مبتكرة أدوية طلائع تصميم
 
  اسراء تيسير محمد قطوش: إعداد
 
 إشراف: البروفيسور رفيق قرمان  
 
 الملخص:
 
 )enimapod() يعانون من نقص في مادة الدوبامينnosnikraPمن المعروف أن مرضى الباركنسون (
الدوبامين. الدوبامين وحده  لذلك كانت المحاولات لتعويض هذا النقص من ،في مناطق معينه في الدماغ 
از هاستطاع العبور إلى الج )apodoveLلا يمر من الحاجز الدموي الدماغي لكن طليعه الليفودوبا (
) عن DL) ليتم تحويله الى الدوبامين في الدماغ. عند اعطاء الليفودوبا (SNCالعصبي المركزي (
من الجرعة تخترق الدماغ. جرعات  % 1مع أقل من  %01طريق الفم  كان التوافر الحيوي له أقل من 
الآثار  كبيرة من الليفودوبا مطلوبة، لأن الكثير منه يتم تحويله إلى الدوبامين خارج الدماغ مما يؤدي إلى
الجانبية التي تشمل الغثيان، التقيؤ، عدم انتظام ضربات القلب وانخفاض ضغط الدم. للحد من التحويل 
 ) عادة ما يعطى الليفودوبا مع مثبط الإنزيمSNCصبي المركزي(إلى الدوبامين خارج الجهاز الع
 ,apodibraC(من الدوبامين مثل  )puorg lyxobrac( مجموعة الكربوكسيل المسئول عن نزع
 جانبية أخرى مركزية عصبية آثار ذلك، من الرغم على). يدابنسيراز و كاربيدوبا( )edizaresneb
 .قائمة تزال لا الجرعة نهاية الحالة عند وتدهور الحركة، كخلل في
 
 ralucelom TFDباستعمال الطرق الحسابية  sgurdorpفي هذا المشروع تم تصميم دوبامين 
بهدف 2MM وحسابات   )p ,d( G13-6 PYL3B   على مستويات مختلفة من  latibro
الأم بسبب توافر حيوي أعلى من الدواء ا من المتوقع أن يكون لهوالتي  sgurdorpالحصول على 
لها فعالية  sgurdorpالمحتمل. علاوة على ذلك، يعتقد بان هذه  gurdorp تحسن امتصاص الدوبامين
 إلى الوصول الخارجي قبل المحيط في الكربوكسيل لنزع يخضع الأخير هذا أكثر من الليفودوبا، لأن
  .الدموي الدماغ حاجز
 
 08
 
 
 يعتمد 5 DorP -1 DorP الدوبامين العمليات في البروتون نقل معدل أن TFD حساب نتائج كشفت
المركزين  بين المسافة وبشكل أساسي على )MG( للمفاعل الهندسية الاختلافات على بشكل كبير
) وقيم rMGحيث وجد ان الانظمة ذات المسافة المنخفضة ( .α الهجوم وزاوية ،rMG ،المتفاعلين
) من  ∆G‡ في هياكلها تظهر معدلات اعلى بكثير (أقل 2DorPو  1DorPالمرتفعة مثل  αالزاوية 
 معدل يرتبطو  3DorP-5DorPمنخفضة مثل  α) و قيمة الزاوية rMGتلك التي لها مسافة مرتفعة  (
 )./1 α (و  rMG مع خطيا ارتباطا التفاعل
 
يتأثر بشكل كبير بقوة   gurdorpلدوبامينلقد وجد أن معدل التحويل الداخلي  ،علاوة على ذلك
اعلى يكون معدل التحويل  niartsحيث ان من تملك  ، لكل من رباعية الاسطوح المتوسطة niarts
 والعكس صحيح. ،الداخلي أقل 
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  سات العلياعمادة الدرا
 جامعة القدس
 
 
 
 
  يالنهج الحساب  -مبتكرة من الدوبامين تصميم طلائع أدوية
 
 
 
 
 إعداد
 اسراء تيسير محمد قطوش
 
 
 
 رسالة ماجستير
 
 
  القدس – فلسطين
 
  
 341/7102
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  يالنهج الحساب  -مبتكرة من الدوبامين تصميم طلائع أدوية
 
 
 
 
  إعداد 
 اسراء تيسير محمد قطوش 
 
 
  فلسطين، جامعة القدس-ريوس صيدلةوبكال
 
 
 
  بروفيسور رفيق قرمان: لرئيسيالمشرف ا
 
 
لوم العقدمت هذه الأطروحة استكمالا لمتطلبات درجة الماجستير في 
  فلسطين.-من كلية الدراسات العليا جامعة القدس الصيدلانية
 
 
  8341/7102
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